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ABSTRACT 
Presented is the first comprehensive study of drugs of abuse on suspended particulate matter 
(SPM) in wastewater. Analysis of SPM is crucial to prevent the under-reporting of the levels 
of analyte that may be present in wastewater.  Analytical methods to date analyse the aqueous 
part of wastewater samples only, removing SPM through the use of filtration or 
centrifugation. The development of an analytical method to determine 60 compounds on 
SPM using a combination of pressurised liquid extraction, solid phase extraction and liquid 
chromatography coupled with tandem mass spectrometry (PLE-SPE-LC-MS/MS) is reported. 
The range of compounds monitored included stimulants, opioid and morphine derivatives, 
benzodiazepines, antidepressants, dissociative anaesthetics, drug precursors, and their 
metabolites. The method was successfully validated (parameters studied: linearity and range, 
recovery, accuracy, reproducibility, repeatability, matrix effects, and limits of detection and 
quantification). The developed methodology was applied to SPM samples collected at three 
wastewater treatment plants in the UK. The average proportion of analyte on SPM as 
opposed to in the aqueous phase was < 5 % for several compounds including cocaine, 
benzoylecgonine, MDMA, and ketamine; whereas the proportion was >10 % with regards to 
methadone, EDDP, EMDP, BZP, fentanyl, nortramadol, norpropoxyphene, sildenafil and all 
antidepressants (dosulepin, amitriptyline, nortriptyline, fluoxetine and norfluoxetine). 
Consequently, the lack of SPM analysis in wastewater sampling protocol could lead to the 
under-reporting of the measured concentration of some compounds. 
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1 INTRODUCTION 
Recent publications have demonstrated the presence of drugs of abuse and associated 
metabolites in the aquatic environment [1-10]. Subsequently, the measured analyte 
concentration is often used to back-calculate drug usage in local communities (so called 
sewage forensics or sewage epidemiology) or to assess the environmental risk posed to 
humans and wildlife. With regards to the analysis of wastewater, all published procedures for 
the analysis of drugs of abuse remove SPM through filtration or centrifugation, and analyse 
the aqueous part of the sample only. However, detailed investigations into the amount of 
compounds sorbed to suspended particulate matter (SPM) are still missing. Without an 
understanding of the amount of compound sorbed onto SPM and the effect of filtration, there 
is potential in the case of some compounds to significantly underestimate the total 
concentration of drug residue in the studied environmental sample.   
Only one limited study has been published to date for the analysis of drugs of abuse on 
SPM by Metcalfe et al. [6]. The study reported the use of ultra-sonication (USE) of SPM to 
assess the levels of methamphetamine, MDA, MDMA, cocaine and benzoylecgonine. This 
study is limited due to the analysis of only two samples in singlet and the relatively small 
number of compounds monitored. While methodologies for the analysis of SPM are lacking, 
many methods have been published for the analysis of soils, sludge and sediment for the 
presence of pharmaceuticals, although the majority of these methods are developed for a 
small range of compounds that are chemically related [11,12]. Kaleta et al. [13] analysed 
sewage sludge using USE for the presence of amphetamine only. Only a few methods have 
been published with regards to the multi-class analysis of pharmaceuticals in solid 
environmental samples. The main parameters of these multi residue methods are summarised 
in Table S1, along with the USE methods developed by Metcalfe et al. [6] and Kaleta et al. 
[13]. 
Typically, methods for the extraction of environmental solids are based on some form of 
sample drying through either air-drying in the dark [14-16], heating in an oven [17], or (most 
commonly) lyophilisation [18-22]. Extraction is generally carried out through the usage of 
pressurised liquid extraction (PLE). PLE is a well-established analytical technique that has 
been used to extract a range of different compounds from numerous different matrices 
[11,12,23]. PLE offers short extraction times, low solvent consumption and provides 
additional extraction by adding an inert material to the extraction cell [11]. Post-treatment of 
extracts typically involves solid phase extraction (SPE) followed by analysis using LC-
MS/MS [16,20-22]. 
An analytical methodology to study drugs of abuse on SPM is critical to prevent under-
reporting of target analytes in wastewater samples. To date only one very limited study has 
been published for this purpose [6]. As a result, there were three major aims of this study:  
1) To develop the first multi-residue method for the analysis of important illicit drugs and 
pharmaceuticals on SPM from several classes of compounds including: stimulants, opioid 
and morphine derivatives, benzodiazepines, antidepressants, dissociative anaesthetics, drug 
precursors, human urine indicators and their metabolites. The post extraction of PLE extracts 
was based on the SPE and LC-MS/MS developed, as previously reported by this group [24]. 
The aim was to develop a relatively straightforward and efficient method based on PLE-SPE-
LC-MS/MS with a single extraction procedure for each of the techniques. 
2) To apply the new method to collect data on the occurrence of the selected analytes on 
SPM in raw wastewater.  
3) Based on data obtained, to assess whether the filtration of wastewater is likely to result 
in significant underreporting of the concentration of analyte in samples.  
 
2 EXPERIMENTAL 
2.1 Chemicals and materials 
Analyte names, CAS number, molecular formula, log Kow, log Dow, pKa and supplier are shown in Table S2. 
Surrogate/internal standards were all purchased from LGC, with the exception of caffeine-d9 (Sigma-Aldrich). 
All standards and internal standards were of the highest purity available (>97%). Individual stock solutions were 
purchased or prepared from powdered substance in either acetone or methanol at a concentration of 1 or 0.1 g 
L
−1
 and stored in the dark at −20 ◦C. Mixed standard solutions were prepared at 10 mg L−1 in methanol and 
diluted as necessary to prepare working solutions. LC-MS mobile phase solvents and additives were all of LC–
MS quality and purchased from Sigma–Aldrich, with the exception of H2O which was purchased from Fisher. 
Hydrochloric acid (37%), ammonium hydroxide (30%), and 5% dimethylchlorosilane (DMDCS) in toluene 
were purchased from Sigma–Aldrich. HPLC grade methanol, glacial acetic acid (>99%) and analytical grade 
sand were purchased from Fisher. Ultrapure water used for PLE was taken from a Barnstead Nanopure water 
purification system (Thermoscientific, UK) with a specific resistance of 18 MΩ-cm. 
Solid phase extraction (SPE) was carried out with Gilson SPE, Aspec XL4 (Anachem, UK). Oasis 60 mg 
MCX and 60 mg HLB cartridges were purchased from Waters (Waters, UK). SPE samples were eluted into 
borosilicate glass tubes (12mm x 75mm, Fisher, UK) and evaporated with a TurboVap LV concentration 
workstation (Caliper, UK). All glassware used was silanised by rinsing (once) with DMDCS for 15 seconds, 
toluene (twice) and finally methanol (thrice). 
Soil and SPM samples were extracted by PLE using an ASE 150 system (Dionex, UK). Whatman glass fibre 
filters were placed at the bottom of 100 mL extraction cells to prevent possible blockage of the end cap. 
Surrogate/internal standards were spiked into each sample at the following concentrations: amphetamine-d11 
(150 ng g
-1
), methamphetamine-d14 (100 ng g
-1
), nicotine-d4 (87.5 ng g
-1
), buprenorphine-d4 (100 ng g
-1
), 
diazepam-d5 (100 ng g
-1
), heroin-d9 (300 ng g
-1
), cocaine-d3(100 ng g
-1
), fentanyl-d5 (100 ng g
-1
), codeine-d6 
(100 ng g
-1
), ketamine-d4 (100 ng g
-1
), fluoxetine-d6 (200 ng g
-1
), propoxyphene-d11 (100 ng g
-1
), oxycodone-
d6 (100 ng g
-1
), norpropoxyphene-d5 (200 ng g
-1
), MDMA-d5 (100 ng g
-1
), oxazepam-d5 (100 ng g
-1
), 
mescaline-d9 (125 ng g
-1
), PCP-d5 (100 ng g
-1
), morphine-d6 (300 ng g
-1
), benzoylecgonine-d8 (100 ng g
-1
), 
LSD-d3 (100 ng g
-1
), methadone-d9 (100 ng g
-1
), EDDP-d3 (100 ng g
-1
), methaqualone-d7 (100 ng g
-1
), 
dihydrocodeine-d6 (100 ng g
-1
), MBDB-d5 (100 ng g
-1
), cocaethylene-d8 (100 ng g
-1
), MDEA-d5 (100 ng g
-1
), 
temazepam-d5 (55 ng g
-1
), caffeine-d9 (600 ng g
-1
) and MDA-d5 (100 ng g
-1
). 
 
2.2 Sample collection and preparation 
Large volume wastewater grab samples (approx. 8 litres) were collected from three major wastewater 
treatments plants (WWTPs) in the UK, once in October and once in November 2011. The three WWTPs served 
populations in excess of 100,000 inhabitants. Samples were collected after primary screening and before any 
secondary treatment. All samples were collected in amber silanised bottles with Teflon faced caps (Fisher, UK). 
Bottles were transported back to the laboratory in a dark and iced coolbox. Wastewater samples were stored in 
the dark at 4 °C for no longer than 18 hours before being processed. All samples were analysed in duplicate. 
A small portion of the wastewater (around 400 mL) was separated from the bulk sample and filtered through 
GF/D 2.7 µm glass fibre filters (Whatman, UK) and subsequently through GF/F 0.7 µm glass fibre filters 
(Whatman, UK). After filtration, samples were acidified with HCl to pH 1.8 and spiked with internal standards. 
Samples were extracted with SPE as described in section 2.4. 
SPM was removed from the bulk wastewater sample using a combination of centrifugation and filtration. 
Bottles used during centrifugation and glass microfibre filters were all oven-dried (40 °C) before use to a 
constant weight. Wastewater was centrifuged at 13,000 rpm (25,931 x g), 10 °C, 18 minutes, with the 
supernatant decanted off and vacuum filtered through GF/D 2.7 µm glass fibre filters (Whatman, UK). Once 
empty, collection bottles were rinsed with a small amount of ultra pure water and filtered to account for any 
remaining residues inside the collection bottles. Centrifuged extracted solids, in addition to the filters and bottles 
used during centrifugation, were oven-dried at 40 °C for approximately 10 hours, until a constant weight was 
achieved. The final dry weight of solids was calculated by taking into account the weight of the centrifuged 
extracted solids, and the final weight of the centrifugation bottles and filters (minus their original oven-dried 
weights before use). Samples were subsequently homogenised and reduced in particle size through the use of a 
pestle and mortar, before being stored in the dark at -18 °C until extraction. Grab samples of soil collected from 
the University of Huddersfield grounds were used for analytical method development and validation, after being 
oven dried at 40 °C for 12 hours and finely ground using a pestle and mortar. Soil was used for method 
development as this matrix, as opposed to SPM, was free of target analytes and easily obtainable. 
 
2.3 Pressurized liquid extraction 
The PLE method was optimised through selection of extraction solvent, extraction temperature and number of 
cycles. Each parameter was investigated in series using initial conditions with regards to PLE as follows: 
temperature, 80 °C; preheat period, 5 min; static cycles, 3; static time, 5 min; flush volume, 60%; purge time, 
250 s; pressure, 1,500 psi and extraction cell, 100 mL. Solvents investigated during optimisation were 
methanol/water (1/1, 1/2, 1/3, 2/1, 2/1, v/v) all adjusted to pH 2 with acetic acid. Temperatures of 40, 60, 80, 
100 and 120 °C were evaluated using the optimised solvent. The number of extraction cycles required was 
optimised by collecting 4 individual extraction cycles of the same sample. During method development, 1 g of 
soil was spiked with 150 ng g
-1
 of each compound, with recoveries calculated against spiked matrix after PLE 
(before SPE). The final PLE method was as follows: temperature, 80 °C; preheat period, 5 min; static cycles, 3; 
static time, 5 min; flush volume, 60%; purge time, 250 s; pressure, 1,500 psi. Three PLE rinse cycles were 
performed before starting PLE analysis and one rinse was carried out between each subsequent sample. 
The extract obtained in PLE (approximately 114 mL) was poured into a 500 mL volumetric. The bottle used 
to collect the PLE extract was then rinsed three times (approximately 300 mL in total) with ultrapure water (pH 
1.8,. adjusted with HCl). The sample was then made up to 500 mL with ultrapure water (pH 1.8) and extracted 
by SPE in the same manner as described in section 2.4. An exception to this was during the investigation into 
extraction solvent, in which samples were diluted to 1000 mL to ensure that the varying amounts of methanol in 
the extract were sufficiently diluted to negate the effects on SPE recovery. 
 
2.4 Solid phase extraction 
SPE was carried out with the usage of Oasis MCX cartridges. Conditioning was performed with MeOH (2 
mL) and equilibration with 2% HCOOH/H2O (2mL, pH 2), both at a flow rate of 3 mL min
−1
. Acidified (pH 
1.8) PLE samples (500 mL) or aqueous wastewater samples (100 mL) were passed through the MCX cartridge 
at a rate of 6 mL min
−1
. Immediately following loading, cartridges were washed with 2 % HCOOH/H2O (2 mL, 
pH 1.8) at a flow rate of 3 mL min
−1
 and subsequently wrapped in aluminium foil and stored at −20 ˚C no longer 
than one week before being eluted. Cartridges were washed with 0.6 % HCOOH/MeOH (2 mL, pH 1.8) at a 
flow rate of 3 mL min
−1
 followed by elution with 7 % NH4OH/MeOH (3 mL) at a flow rate of 1 mL min
−1
 into 
silanised vials. Extracts were evaporated to dryness (40 ˚C, N2, 2–10 psi) and reconstituted with 0.3 % 
CH3COOH/5 % MeOH/H2O (v/v) (500 µL). All samples were filtered through 0.2 µm PTFE filters (Whatman, 
Puradisc, 13mm) before being transferred to maximum recovery deactivated vials with PTFE septa (Waters, 
UK). 
 
2.5 LC-MS/MS 
The aforementioned drug residues and associated metabolites were measured with a fully validated, highly 
selective and sensitive LC-MS/MS method [24]. Briefly, separation was achieved with the usage of Waters 
ACQUITY UPLC
TM
 system (Waters, UK) consisting of ACQUITY UPLC
TM
 binary solvent manager and 
ACQUITY UPLC
TM
 sample manager. Analytes were analysed with an AQUITY UPLC BEH C18 (1.7 µm; 
1mm × 150 mm) column, with a mobile phase consisting of mobile phase A (pH 2.9): 79.7%H2O, 20%MeOH, 
0.3%CH3COOH and mobile phase B (pH 3.3): 99.7%MeOH, 0.3%CH3COOH at a flow rate of 0.04 mL min
-1 
and a temperature of 30 °C. The gradient programme was as follows: 0min – 100% A, 17 min – 41.3% A, 17.2 
min – 0% A, 20.2 min – 0% A, 20.3 min – 100% A, 34.0 min – 100% A. An injection volume of 20 µL was 
used. 
A triple quadrupole mass spectrometer (TQD, waters, UK) equipped with an electrospray ionisation source 
was used for the quantification of target analytes. The analyses were performed in positive mode. The mass 
spectrometer was operated in selected reaction monitoring (SRM) mode, measuring the fragmentation of the 
protonated pseudo-molecular ions of each compound. Masslynx 4.1 software (Waters, UK) was used to collect 
and analyse all data. 
 
2.6 Quantification and confirmation 
Each compound was quantified by MRM, with the protonated molecular ion employed as the precursor. The 
most abundant transition product ion was typically used for quantification; with a second transition, for nearly 
all compounds, used for confirmation (see Table S3). The criteria to confirm the presence of analyte in 
environmental samples included ensuring the ratio of the retention time of internal standard/analyte in the 
standard sample was within 2.5 % of the ratio of internal standard/analyte in the ‘test’ sample. Furthermore, 
ensuring the ion ratio of the quantifier ion to that of the qualifier ion was within tolerance ranges as described by 
the EU guidelines [25]. 31 deuterated internal standards were used to compensate for signal suppression or 
enhancement of analytes in the ESI source and low SPE or PLE recoveries. A deuterated internal standard for all 
analytes was not possible due to lack of commercial availability; hence an internal standard that was similar in 
structure and gave similar analytical responses was selected as a surrogate for those compounds. 
 
The percentage of analyte on SPM (PSPM) was experimentally determined using Equation 1: 
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)        
     
Equation 1 – Experimentally determined percentage of analyte sorbed onto SPM  
 
Where: CSPM is the concentration of analyte determined on SPM (g g
-1
); MSB is the dry weight of SPM in the 
wastewater sample (g L
-1
); VW is the volume of wastewater sample (L); CDISS is the concentration of analyte in 
the aqueous phase of the sample (ng L
-1
). 
 
2.7 Method validation 
The performance of the method was evaluated through estimation of linearity and range, recovery, accuracy, 
reproducibility, repeatability, matrix effects, and limits of detection and quantification. All results expressed as 
ng g
-1 
are done so on a dry-weight basis. 
Linearity was investigated over a ten-point calibration with spiked soil samples ranging from 0.5 – 500 ng g-1 
analysed in duplicate. The calibration curve was prepared by calculating the ratios between the peak area of 
each substance and the peak area of the internal standard. Masslynx 4.1 software was used to analyse and 
process all data. Acceptable linearity was obtained with a correlation coefficient >0.99 with ≥5 data points. 
Overall method repeatability was evaluated by spiking soil samples with 50 ng g
-1
 of each compound (n = 5). 
Overall method reproducibility was evaluated at 50 ng g
-1
 over a three day period (n = 2). Accuracy of the 
method was assessed as the percentage deviation from the known amount of analyte added to the sample at one 
concentration level, 50 ng g
-1
. 
Recoveries regarding the PLE procedure and the overall PLE-SPE-LC-MS/MS were evaluated by spiking 
both soil and SPM at 50 ng g
-1
. To calculate the PLE recovery, peak areas of analytes in soil/SPM spiked before 
PLE were compared to peak areas of analytes in soil/SPM extract spiked after PLE but before SPE. To calculate 
PLE-SPE-LC-MS/MS recovery, peak areas of analytes in soil/SPM spiked before PLE were compared to peak 
areas of analytes in soil/SPM extract spiked during reconstitution step (after SPE). The recovery for the SPE-
LC-MS/MS procedure was calculated by spiking soil/SPM after PLE (but before SPE) and comparing peak 
areas of analytes in soil/SPM spiked after PLE with peak areas in soil/SPM extract spiked during reconstitution. 
Thus each recovery is decoupled from matrix effects. Matrix effects are presented separately and were 
determined for each compound as a percentage decrease in peak area of analyte in sample matrix (minus peak 
area present in blank sample) compared to sample diluent. 
LC-MS/MS instrumental detection limits (IDL) and quantification limits (IQL) were experimentally determined 
using signal-to-noise approach through analysis of a series of low concentration standards (in spiked sample 
diluent) as previously reported [24]. IDL was determined at the lowest concentration that provided S/N ≥ 3 for 
transition 1. IQL limits were determined at the lowest concentration that provided S/N ≥ 10 for transition 1 and 
S/N ≥ 3 for transition 2. PLE-SPE-LC-MS/MS method detection limits (MDL) and method quantification limits 
(MQL) were determined using soil spiked with known concentrations of analytes and then extracted according 
to the procedure described above.  MQLs were determined both experimentally with the usage of signal-to-noise 
approach (MDLS/N, MQLS/N) and calculated with the usage of Eqs 2 and 3 (MDLcalc, MQLcalc). To estimate 
MDLcalc and MQLcalc the IDL and IQL was taken into consideration in addition to the total method recovery 
(including matrix effects) and the sample concentration factor involved. To clarify, this process firstly involved 
estimating the instrumental limits for solid samples as opposed to liquid. For instance, if the IQL for a certain 
analyte was 100 ng L
-1
 (the equivalent of 50 ng 500 mL
-1
), and as the solid sample (1 g) is diluted in 500 mL, 
this allows an instrumental quantification limit of 50 ng g
-1
 to be estimated for the solid sample (termed S.IQL) 
(assuming no loss of analyte at any step in the procedure or no concentration factor at this point). Subsequently, 
once a S.IQL or S.IDL has been estimated for the analyte, Equation 2 and Equation 3 may be used to take into 
consideration total method recovery (that includes matrix effects) and the concentration factor. 
              
           
         
         
Equation 2 – PLE-SPE-LC-MS/MS method detection limit calculation 
 
         
           
          
 
Equation 3 - PLE-SPE-LC-MS/MS method quantification limit calculation 
 
Where: S.IDL is the instrumental detection limit (ng g
-1
) (see above for discussion), S.IQL is the instrumental 
quantification limit (ng g
-1
), T.Rec is the total PLE-SPE-LC-MS/MS recovery (%) and CF is the concentration 
factor, which in this method denotes 1000. 
Spiking was carried out by loading the soil (1 g) or SPM (1 g) into an extraction cell partially filled with sand 
and spiking with a small volume of internal standards in methanol (10 µL) (and analytes in the case of recovery 
experiments). The extraction cell was then placed in a fume cupboard for 20 minutes to allow the solvent to 
evaporate and the remaining cell filled with sand. 
 
3 RESULTS AND DISCUSSION 
3.1 Method development 
To achieve a fast and efficient extraction procedure, the PLE variables (solvent, 
temperature and extraction cycles) were evaluated. Each PLE parameter was investigated in a 
step-wise manner using the initial conditions described in section 2.3. Initial conditions were 
selected based on a literature review, with the most relevant methods to this study 
summarised in Table S1. The variety of compounds studied exhibited Log D values in the 
range -2.3 – 4.7 at pH 7 and -1.9 -5.4 at pH 8 (predicted using ACD labs software [26]). 
The PLE method was developed based on the SPE and LC-MS/MS procedure described 
previously [24]. The SPE method was optimised by evaluating the percentage of organic 
solvent that a sample can contain before recovery is adversely affected. This parameter is 
important due to the need to dilute PLE extracts to reduce organic composition; generally so 
organic content is around 5 % or less [20,27]. It was found with the use a mixed mode SPE 
sorbent that methanol content may be up to 25 %, thereby significantly reducing the required 
dilution of PLE extracts and in turn the amount of time required for extraction. This study is 
described in more detail in the supplementary material. 
 
3.1.1 Solvent  
As with the majority of solid-liquid extraction techniques, solvent is one of the most 
important parameters to optimise in the development of an efficient extraction procedure 
[11]. Due to the range of compounds selected in this study being characterised by widely 
differing polarities, a solvent with some organic content in water was likely to provide the 
best recoveries. Consequently, various different solvents were tested containing varying 
amounts of methanol/water (1/1, 1/2, 1/3, 2/1, 2/1, v/v) with all solvents adjusted to pH 2 
with acetic acid. The combination of methanol/water, as opposed to other solvents such as 
acetonitrile/water, was selected based on published literature identifying this mixture as 
providing higher recoveries in the majority of extraction methods [16,18,20,21]. It was 
decided to test the solvents at an acidic pH due to authors [18,28,29] reporting the highest 
recoveries with an acidic solvent.  
To optimise the solvent, soil was directly spiked with 150 ng g
-1
 of each compound and 
extracted with methanol/water (pH 2) at different ratios. Absolute recoveries were calculated 
against soil that was spiked after PLE, but before SPE. Thus, recoveries are a reflection of 
PLE recovery decoupled from matrix effects. Recoveries are shown in Table S5 with the 
highest recovery obtained for each compound highlighted. 
As was expected with multi-residue analysis, the results did not show one particular solvent 
to provide the highest recoveries for all compounds. Some analytes reported very little 
change in all solvents tested, including cocaine, benzoylecgonine, cocaethylene, MDA, 
MDMA, 6-acetylmorphine, ketamine and norketamine. In comparison, some compounds 
showed much higher recoveries in certain solvents. EDDP reported a recovery of 82 % with 
methanol/water at 1/1 (v/v), as opposed to a recovery of 52 % at 3/1 and 65 % at 1/3. 
Methadone also provided a similar recovery pattern to that of its main metabolite EDDP. All 
of the amphetamine type compounds provided highest recoveries when extracted in the 
solvent containing the highest percentage of water. The antidepressants all reported highest 
recoveries when extracted using methanol water, 1/1. For instance fluoxetine achieved a 
recovery of 84 % in methanol/water, 1/1 (v/v), whereas a recovery of 23 % was obtained at 
1/3 and 67 % at 3/1. Similarly, the benzodiazepines reported optimal recoveries in the same 
solvent, with exception of temazepam and oxazepam that reported higher recoveries with an 
increased amount of methanol. Recoveries were < 30 % in all solvents tested for fentanyl, 
BZP, PCP and 7-aminonitrazepam. As a compromise between the optimal recoveries for all 
compounds, a solvent containing methanol/water, 1/1 (v/v) was selected for further 
development. 
 
3.1.2 Temperature 
Application of higher temperatures in PLE decreases the viscosity of solvents, therefore 
allowing better penetration into sample matrix [27]. Furthermore, higher temperatures 
increase diffusion rates and increase the ability of the solvent to disrupt matrix-analyte 
interactions. Consequently, the release of analytes from active sites in the matrix is speeded 
up, which is considered the rate-limiting step in many environmental applications [23]. Low 
temperature can decrease recoveries. However, on the other hand, too high a temperature can 
also decrease recoveries. This may be due to thermal degradation of analytes or loss of 
selectivity in the method that leads to the more efficient release of interfering matrix 
components [11,20,28]. Temperatures of 50 to 110 °C were studied by Vazquez-Roig et al. 
[22] and found increasing recoveries up to 90 °C. Over this temperature the recovery of some 
pharmaceuticals decreased. Similarly, Barron et al. [20] studied a temperature range of 40 to 
120 °C and selected the optimum temperature of 60 °C due to loss of some compounds over 
this temperature.  
In this study, temperatures of 40, 60, 80, 100 and 120 °C were studied using the optimised 
solvent methanol/water, 1/1 (v/v) at pH 2. Soil was directly spiked with 150 ng g
-1
 of each 
compound. Absolute recoveries were calculated in the same manner as previously undertaken 
during the solvent investigation. Absolute recoveries were calculated against soil that was 
spiked after PLE, but before SPE; hence recoveries are a reflection of PLE recovery 
decoupled from matrix effects. Recovery values for all analytes at each temperature are listed 
in Table S6. 
The increase in temperature resulted in changes in recovery for a number of compounds. 
For the majority of compounds an increase in recovery was observed as the temperature 
increased from 40 °C. However, for some compounds after a certain temperature a decrease 
in recovery was observed. The negative effect of an increase in temperature is shown in 
Figure S1a, with a decrease in recovery observed after 60 - 80 °C. As previously mentioned, 
this may be due to thermal degradation of analytes or loss of selectivity that occurred as a 
result of a less selective method extracting more interfering matrix components [11,20,28]. In 
contrast, the trend observed for certain compounds showed a continual increase in recovery 
with temperature (see Figure S1b). The increase in recovery with temperature was especially 
pronounced for PCP, venlafaxine and EDDP. For instance, at 40 °C venlafaxine reported a 
recovery of 20 %, while at 120 °C a recovery of 95 % was observed. A temperature of 80 °C 
was selected for further development as a compromise between the optimum recoveries for 
the studied compounds. 
 
3.1.3 Extraction cycles 
The number of cycles employed in PLE is important as the introduction of fresh solvent 
maintains a suitable solvent-to-sample equilibrium, and improves partitioning into the liquid 
phase [11,23]. A static time of 5 minutes was selected based on the vast majority of authors 
reporting 5 minutes as the optimal static period [16,20,21,27]. To investigate the number of 
extraction cycles required soil was spiked with 150 ng g
-1
 of each compound. Four successive 
extractions were carried out on the same sample with each cycle collected and analysed 
separately. Results shown in Figure S2 are expressed as cumulative absolute recovery. 
Absolute recovery was calculated by comparison of peaks areas to a sample of blank soil 
spiked after PLE, but before SPE.  
It was found that the first and second cycle contained the highest concentrations of each 
analyte with only a small fraction of each compound detected in the third cycle, and 
negligible amounts of each analyte detected in the fourth cycle. For this reason three cycles 
were selected as optimum.  
 
3.2 Method validation 
The performance of the method was evaluated through estimation of linearity and range, 
recovery, accuracy, reproducibility, repeatability, matrix effects, and limits of detection and 
quantification. All method performance data is listed in Table 1 and recoveries in Table 2. 
LC-MS/MS chromatograms for all analytes spiked on SPM before PLE at 50 ng g
-1
 are 
shown in Figure S3. 
Soil samples were spiked in the concentration range 0.5 - 500 ng g
-1
 and calibration curves 
generated as described in section 2.7. The range was selected based on expected 
concentrations on SPM in wastewater samples. Acceptable linearity was considered R
2
 ≥ 0.99 
with a minimum of n = 5 data points. The correlation coefficient for all compounds was R
2 
> 
0.992 with the majority of compounds achieving linearity of R
2
 > 0.997 (Table 1). An 
exception to this was fentanyl (R
2
 = 0.979). The range for the majority of compounds 
incorporated all ten data points between the range 0.5 - 500 ng g
-1
. Sensitivity for some 
compounds was above 0.5 ng g
-1
 (12 in total: ecgonidine, BZP, BDB, mescaline, 
oxymorphone, norpropoxyphene, nortramadol, temazepam, nitrazepam, norfluoxetine, 
sildenafil and norephedrine), and so was measured at a higher starting concentration. The 
upper concentration range was < 250 ng g
-1
 for a small number of compounds (6 in total: 
anhydroecgonine methyl ester, ecgonidine, TFMPP, BDB, oxymorphone and methaqualone), 
which could be due to several factors such as SPE breakthrough or the concentration being 
above the linear range of the mass spectrometer. Nevertheless, with a minimum of n = 5 data 
points, the calibration curve was considered acceptable for quantification purposes. 
MDLs and MQLs were estimated based on a signal to noise approach as described in 
section 2.7. MQLs obtained in soil were < 1.0 ng g
-1 
for 56 compounds and on SPM < 2.6 ng 
g
-1 
for 54 compounds (Table 1). This method therefore offers excellent sensitivity for the 
quantification of multi-class compounds at trace levels. High limits of quantification for a 
small percentage of compounds were reported. This was a result of low PLE recovery (BZP, 
fentanyl), low SPE recovery (anhydroecgonine methyl ester, ecgonidine) or high ion 
suppression when extracted from SPM (diazepam, nordiazepam, and mescaline).  
Repeatability was assessed at a concentration of 50 ng g
-1
 with n = 5 samples, with 
reproducibility conducted at the same concentration over a three day period. Precision < 20 % 
was considered acceptable due to the number of analytical steps involved in the procedure. 
Repeatability was determined to be ≤ 10 % for nearly all compounds (56 analytes), whilst on 
the other hand a small number of compounds reported values > 20 % including fentanyl (31 
%), fluoxetine (37 %) and norfluoxetine (35 %). Reproducibility was < 15 % for 55 
compounds, with values > 20 % for analytes BZP (42 %), fluoxetine (48 %) and 
norfluoxetine (52 %). All compounds reported an accuracy ± 18 % that was considered 
adequate for environmental application. 
Recovery was determined by spiking soil and SPM at 50 ng g
-1
 for each analyte. 
Recoveries were calculated as described in section 2.7. Absolute recoveries were determined 
in relation to 1) the PLE method, 2) the SPE method (including evaporation and 
reconstitution), and 3) the full PLE-SPE-LC-MS/MS method. Relative recovery was 
determined for the full procedure and all recoveries are listed in Table 2. PLE-SPE-LC-
MS/MS recoveries for the majority of compounds (38 in total) were ≥ 60 % in soil, and 
similarly in SPM recoveries were ≥ 60 % for most analytes (34 in total). By providing 
recoveries for the SPE and PLE procedure separately, observations as to why low recoveries 
have been reported can be extracted. For instance, temazepam in both soil and SPM reported 
a PLE recovery around 90 %, whereas the SPE recovery was around 10 %, resulting in a low 
PLE-SPE-LC-MS/MS recovery. The use of deuterated internal standards to compensate for 
sample preparation and matrix effects provided recoveries of around 100 % for all 
compounds, with a small number of exceptions. When analysed on SPM, low relative 
recoveries were obtained for anhydroecgonine methyl ester (11 %), ecgonidine (7 %) and 
methcathinone (20 %).  
MS signal suppression or enhancement was investigated by spiking soil/SPM at 100 µg L
-1
 
during reconstitution and comparing peak areas to that of sample diluent spiked at the same 
concentration. The results are listed in Table 1, with a value of 0 % indicating no matrix 
effect, > 0 % indicating signal suppression and a value < 0 % indicating signal enhancement. 
For the majority of compounds in soil, a small amount of enhancement or suppression of 20 
% or less was observed. Surprisingly high signal enhancement was observed in soil for 
nortramadol (118 %) and norephedrine (212 %). Matrix effects in SPM were more 
pronounced. Although matrix effects were different for every compound, many compounds 
observed signal suppression in the range of 20 - 50 %. The highest signal suppression was 
observed for nordiazepam at 97 %, with the parent compound diazepam also high at 87 %. 
Signal enhancement was again observed for norephedrine (363 %) and tramadol (300 %). In 
addition, significant enhancement was observed for amphetamine (118 %), propoxyphene 
(191 %), norfluoxetine (165 %) and ephedrine (123 %). Radjenovic et al. [21] also observed 
extremely high signal suppression in sewage sludge, albeit with a different set of compounds, 
with enhancement of: acetaminophen 121.7 – 311.1 %, propyphenazone 246 – 375.7 %, 
sulfamethoxazole 272 – 361.1 %, glibenclamide 177.1 – 384.4 % and ofloxacin 626.7 – 669.4 
%. 
 
4 Application to samples from the UK  
4.1 Results 
The developed methodology was applied to the analysis of SPM extracted from wastewater 
collected from three major WWTPs in the UK. Of the SPM samples analysed, 31 compounds 
were determined at a concentration >MQL, with a further three compounds detected at a 
concentration MDL> < MQL. The concentration of analyte measured on SPM and dissolved 
in the aqueous phase is listed in Table 3. This table also reports the percentage of the total 
concentration that was measured on SPM. 
The adsorption of cocaine to SPM ranged from 1.8 – 2.7 ng g-1, which represented a 
proportion on SPM ranging from 0.9 – 1.8 %. To a lesser extent, benzoylecgonine was 
determined on SPM as a proportion ranging from 0.02 to 0.2 % and cocaethylene 1.4 – 2.2 %. 
Amphetamine was detected in four samples. However, the ion ratio of the two transitions for 
this compound was outside the permitted tolerance range and did allow reliable 
quantification. Nevertheless this compound was presented in the results for information 
purposes. Amphetamine presented a proportion on SPM ranging from 1.6 – 8.6 %. 
Methamphetamine was not detected in wastewater or sorbed to SPM. 
Levels of methadone and EDDP detected on SPM were found to be important. The 
concentration of methadone ranged from 19.4 - 57.6 ng g
-1
, resulting in a proportion on SPM 
of 8.1 -18.6 %. EDDP concentration was between 30.1 – 194.0 ng g-1 providing a proportion 
of particulates of 12.1 - 34.5 %. Similarly, EMDP reported a proportion of 26.2 - 32.1 %, 
although it should be noted that these values are based on two samples only. Concentrations 
of codeine, norcodeine, morphine, normorphine, tramadol and dihydrocodeine were detected 
on SPM, with the proportion < 5.6 % in all samples for each compound. 
The concentration of studied antidepressants on SPM was relatively high. The highest 
concentration determined in this study was for amitriptyline, which ranged from 118.3 – 
629.9 ng g
-1
 and resulted in a proportion on solids of 9.4 – 50.3 %. The highest partitioning to 
solids was determined for fluoxetine, 39.2 – 73.9 %, and norfluoxetine, 36.7 - 89.4 %. 
Dosulepin reported a proportion on solids ranging from 17.4 – 64.7 %, whilst in contrast, 
venlafaxine was determined at 0.6 - 3.9 %.  
 
4.2 Data Evaluation 
One of the goals of this study was to assess whether or not the adsorption of target drug 
residues to SPM was at sufficient levels to obstruct the reliable estimation of drug usage 
through the analysis of the aqueous part of the WWTP influent sample only. The proportion 
of sorption to SPM is shown in Figure 1. The maximum proportion of analyte sorbed to SPM 
was < 2.8 % (thus likely to be considered negligible) for cocaine, benzoylecgonine, 
cocaethylene, MDMA, temazepam and ketamine. Furthermore sorption was < 4.7 % for 
norcodeine, normorphine, dihydrocodeine, tramadol, oxazepam and nortriptyline. Therefore, 
publications in which these compounds have been monitored will not be adversely affected 
with regards to the lack of SPM analysis. 
In contrast, the proportion of analyte on SPM could be a cause for concern in relation to 
some target analytes. Morphine was determined up to a maximum of 5.6 % on SPM, codeine 
up to 5.2 % and amphetamine up to 8.6 %. Although these values are still relatively low, 
ideally SPM analysis would be carried out to prevent under-reporting.  
The proportion of analyte on SPM for methadone was in the range 8.1 - 18.6 % (mean = 
11.5 %), and EDDP, 12.1 – 34.5 % (mean = 18.5 %). The high percentage of analyte on SPM 
necessitates the analysis of SPM. EDDP was used as an indicator for methadone usage by van 
Nuijs et al. [9], with the authors reporting extremely low average consumption of methadone 
(2 mg/day per 1000 inhabitants). The same publication also reports that the use of methadone 
is uncommon in Europe based on official EMCDDA statistics. It is not clear in this 
publication whether or not the levels of methadone determined from EDDP were lower than 
expected in comparison to official statistics, as use was considered negligible in the country 
where the study was performed (Belgium). However, based on the findings of this study, 
methadone could have been under-reported by wastewater analysis alone by as much as 35 
%. Methadone was employed as the consumption indicator of methadone itself in the work 
by Postigo et al. [8]. Therefore, based on the results of this study, levels could have possibly 
been under-reported by up to nearly 20 %. 
The partitioning of analytes onto SPM was most significant for antidepressant compounds, 
which is not surprising given their non-polar nature (see Table S2). The proportion of analyte 
on SPM was determined at a maximum for dosulepin 64.7 %, amitriptyline 50.3 %, 
nortriptyline 39.7 %, fluoxetine 73.9 % and norfluoxetine 89.4 %. Somewhat lower than the 
other antidepressants, venlafaxine was determined at a maximum proportion on solids of 3.9 
%, which is likely to be a result of the analyte’s more polar nature. High levels of fluoxetine 
were determined in bio solids collected from a WWTP by Kinney et al. [30], ranging from 
100 to 4700 ng g
-1
organic carbon and by Radjenovic et al. [21] ranging from 71.9 – 122.7 ng g
-1
.  
 
5 CONCLUSIONS 
 
This study reports the first PLE methodology for the extraction of drugs of abuse on 
suspended particulate matter in wastewater. The PLE-SPE-LC-MS/MS procedure developed 
allows the simultaneous quantification of a wide range of drugs of abuse from complex 
environmental matrices. Suspended particulate matter was analysed from the UK providing 
the first comprehensive report of drugs of abuse on SPM.  
The developed PLE protocol was optimised through the evaluation of key parameters, 
including solvent, temperature and number of extraction cycles. A previously developed SPE 
procedure was used to concentrate PLE extracts, which was further evaluated to assess the 
impact of higher sample methanol content. This in turn allowed a lower PLE extract dilution 
volume to be utilised in comparison to other published manuscripts, which recommend a 
methanol content < 5 %. The methodology was validated through assessment of linearity and 
range, recovery, accuracy, reproducibility, repeatability, matrix effects, and sensitivity. PLE-
SPE-LC-MS/MS recoveries were ≥ 60 % for the majority of compounds when extracted from 
SPM. Excellent quantification levels were provided for nearly all compounds (54 in total) at 
< 2.6 ng g
-1
. 
The application of the method to wastewater samples allowed for quantification of 34 
compounds on SPM in the range 0.1 (benzoylecgonine) – 629 (amitriptyline) ng g-1. For the 
majority of compounds this constituted a proportion on SPM < 5 %, although certain 
compounds reported significant levels. The average proportion on SPM was > 10 % with 
regards to methadone, EDDP, EMDP, BZP, fentanyl, nortramadol, norpropoxyphene, 
sildenafil and all antidepressants (dosulepin, amitriptyline, nortriptyline, fluoxetine and 
norfluoxetine).  
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FIGURES 
Figure 1. Experimentally determined proportion of analyte sorbed onto SPM collected from wastewater influent 
in the UK. White dots represent the mean value, with blue lines representing the range. The number of samples 
for which the analyte was quantified is shown in brackets next to each compound. 
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TABLES 
Table 1.  Performance data for studied compounds extracted by PLE-SPE-LC-MS/MS 
Compound 
Soil 
 
Suspended particulate matter   Internal standard 
  
tR
 
(min) 
R
2
 
Linearity 
range (ng g
-1
) 
Repeat. 
(% RSD) 
(n = 5) 
Reprod. 
(% RSD)    
( n = 3) 
Accur. 
(%)                   
(n = 3) 
MDLcalc                 
(ng g
-1
) 
MQLcalc                   
(ng g
-1
) 
MQLS/N 
(ng g
-1
) 
MS matrix 
effect (%)                      
(n = 3) 
MDLcalc              
(ng g
-1
) 
MQLcalc                  
(ng g
-1
) 
MS matrix 
effect (%)                       
(n = 2)   
Stimulants 
          
 
          
  
Cocaine 11.1 0.999 0.5 - 500 6 4 -6 0.02 0.07 0.05 9 ± 6 
 
0.02 0.08 20 ± 2 
 
Cocaine-D3 
Benzoylecgonine 10.6 0.998 0.5 - 500 2 5 6 0.02 0.07 0.03 9 ± 5 
 
0.02 0.10 13 ± 1 
 
Benzoylecgonine-D8 
Norbenzoylecgonine 11.2 0.999 0.5 - 500 3 3 2 0.02 0.08 0.02 15 ± 4 
 
0.02 0.09 24 ± 1 
 
Benzoylecgonine-D8 
Norcocaine 12.1 0.999 0.5 - 500 4 10 5 0.01 0.06 0.03 -13 ± 10 
 
0.02 0.06 -7 ± 1 
 
Cocaine-D3 
Cocaethylene 13.2 0.999 0.5 - 500 5 4 4 0.02 0.09 0.01 24 ± 2 
 
0.02 0.09 34 ± 1 
 
Cocaethylene-D8 
Anhydroecgonine M. E. 3.3 0.995 0.5 - 100 7 10 3 0.16 0.78 0.53 24 ± 4 
 
1.87 9.33 73 ± 1 
 
Cocaine-D3 
Ecgonidine  2.9 0.996 5.0 - 200 17 7 7 0.77 3.84 2.44 42 ± 3 
 
4.07 20.33 70 ± 2 
 
Benzoylecgonine-D8 
Amphetamine   6.2 0.999 0.5 - 500 4 6 -8 0.05 0.25 0.17 -20 ± 19 
 
0.05 0.23 -118 ± 10 
 
Amphetamine-D11 
Methamphetamine  6.8 0.999 0.5 - 500 3 1 -11 0.02 0.06 0.05 -4 ± 12 
 
0.02 0.08 -17 ± 1 
 
Methamphetamine-D14 
Methcathinone 4.6 0.999 0.5 - 500 7 14 3 0.04 0.25 0.15 -68 ± 24 
 
0.18 1.19 -54 ± 5 
 
Methamphetamine-D14 
BZP 3.7 0.994 5.0 - 500 21 42 1 1.31 2.62 0.31 -9 ± 4 
 
1.61 3.23 58 ± 0 
 
PCP-D5 
TFMPP 13.7 0.997 0.5 - 200 5 5 7 0.02 0.08 0.07 2 ± 6 
 
0.02 0.09 16 ± 0 
 
PCP-D5 
           
 
           
Hallucinogens 
          
 
           
MDA  6.9 0.999 0.5 - 500 3 3 -4 0.04 0.37 0.20 7 ± 9 
 
0.05 0.48 5 ± 3 
 
MDA-D5 
MDMA 7.1 0.999 0.5 - 500 2 1 6 0.02 0.08 0.08 5 ± 6 
 
0.03 0.10 21 ± 3 
 
MDMA-D5 
MDEA 8.8 0.998 0.5 - 500 2 4 10 0.02 0.08 0.07 7 ± 6 
 
0.02 0.08 17 ± 1 
 
MDEA-D5 
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MBDB 9.9 0.998 0.5 - 500 4 6 -13 0.02 0.08 0.03 14 ± 5 
 
0.02 0.07 10 ± 1 
 
MBDB-D5 
BDB 10.0 0.992 0.5 - 150 7 12 -18 0.06 0.39 0.17 10 ± 8 
 
0.04 0.25 -41 ± 2 
 
MBDB-D5 
Mescaline 5.7 0.999 5.0 - 500 3 2 -5 0.29 0.59 0.76 -9 ± 12 
 
2.87 5.74 85 ± 1 
 
Mescaline-D9 
LSD 13.1 0.998 0.5 - 500 4 6 5 0.03 0.12 0.05 18 ± 2 
 
0.02 0.09 27 ± 0 
 
LSD-D3 
O-H-LSD 8.6 0.999 0.5 - 500 4 10 5 0.03 0.10 0.02 14 ± 5 
 
0.03 0.13 31 ± 0 
 
LSD-D3 
           
 
           
Opioids and morphine derivatives 
   
 
           
Heroin 10.8 0.999 0.5 - 500 4 3 -5 0.07 0.47 0.10 7 ± 3 
 
0.09 0.60 26 ± 2 
 
Heroin-D9 
6-acetylmorphine 5.3 0.999 0.5 - 500 9 9 -3 0.04 0.29 0.09 -7 ± 7 
 
0.07 0.50 29 ± 2 
 
Codeine-D6 
Codeine 4.0 0.999 0.5 - 500 3 2 1 0.05 0.30 0.16 2 ± 7 
 
0.17 1.15 69 ± 0 
 
Codeine-D6 
Norcodeine 4.1 0.998 0.5 - 500 4 1 -12 0.06 0.29 0.28 -6 ± 9 
 
0.15 0.73 44 ± 0 
 
Codeine-D6 
Oxycodone 4.5 0.998 0.5 - 500 4 3 3 0.05 0.35 0.12 1 ± 6 
 
0.15 0.97 36 ± 1 
 
Oxycodone-D6 
Oxymorphone 3.3 0.997 0.5 - 200 4 2 8 0.05 0.35 0.33 -8 ± 7 
 
0.32 2.10 29 ± 0 
 
Oxycodone-D6 
Morphine 3.2 0.998 0.5 - 250 8 4 4 0.07 0.36 0.22 -2 ± 9 
 
0.35 1.73 62 ± 5 
 
Morphine-D6 
Normorphine 3.2 0.997 0.5 - 250 6 2 7 0.09 0.46 0.45 12 ± 5 
 
0.51 2.53 69 ± 3 
 
Morphine-D6 
Dihydrocodeine 3.9 0.998 0.5 - 500 3 3 4 0.05 0.32 0.06 -1 ± 2 
 
0.15 1.02 45 ± 1 
 
Dihydrocodeine-D6 
Buprenorphine 16.4 0.997 0.5 - 250 7 2 8 0.15 0.73 0.19 27 ± 2 
 
0.17 0.84 61 ± 2 
 
Buprenorphine-D4 
Norbuprenorphine 14.4 0.996 0.5 - 250 8 7 12 0.12 0.60 0.17 21 ± 1 
 
0.12 0.59 42 ± 1 
 
Buprenorphine-D4 
Methadone 19.1 0.999 0.5 - 500 9 8 3 0.02 0.07 0.02 4 ± 7 
 
0.03 0.11 49 ± 3 
 
Methadone-D9 
EDDP 15.7 0.997 0.5 - 500 10 6 -15 0.05 0.20 0.06 26 ± 2 
 
0.04 0.18 62 ± 7 
 
EDDP-D3 
EMDP 20.3 0.997 0.5 - 500 12 3 3 0.03 0.11 0.04 4 ± 4 
 
0.03 0.10 21 ± 3 
 
Methadone-D9 
Fentanyl 14.5 0.979 0.5 - 150 31 15 19 0.06 0.24 0.04 22 ± 2 
 
0.03 0.10 36 ± 2 
 
Fentanyl-D5 
Norfentanyl 10.4 0.996 0.5 - 500 5 4 9 0.02 0.08 0.02 12 ± 6 
 
0.03 0.12 23 ± 1 
 
Dihydrocodeine-D6 
Propoxyphene  18.6 0.999 0.5 - 500 4 5 -4 0.03 0.34 0.10 -87 ± 25 
 
0.02 0.25 -191 ± 3 
 
Propoxyphene-D11 
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Norpropoxyphene 19.0 0.997 5.0 - 500 7 7 -15 0.49 2.45 1.12 -66 ± 19 
 
0.38 1.90 -91 ± 21 
 
Norpropoxyphene-D5 
Tramadol 10.7 0.998 0.5 - 500 2 2 11 0.03 0.34 0.04 11 ± 3 
 
0.06 0.62 47 ± 1 
 
Codeine-D6 
Nortramadol 11.7 0.997 5.0 - 500 6 19 -8 0.30 1.51 3.83 -118 ± 25 
 
0.18 0.92 -300 ± 22 
 
Codeine-D6 
           
 
           
Benzodiazepines 
          
 
           
Temazepam 22.2 0.997 0.5 - 500 5 2 -4 0.10 0.41 0.29 3 ± 2 
 
0.21 0.86 -1 ± 2 
 
Temazepam-D5 
Diazepam  23.1 0.999 0.5 - 500 1 6 4 0.06 0.43 0.02 24 ± 1 
 
0.44 2.93 87 ± 1 
 
Diazepam-D5 
Nordiazepam  22.8 0.999 0.5 - 500 3 6 -5 0.06 0.39 0.02 4 ± 5 
 
2.44 16.26 97 ± 0 
 
Diazepam-D5 
Nitrazepam 19.9 0.996 0.5 - 500 5 16 -2 0.07 0.44 0.10 -8 ± 6 
 
0.09 0.58 3 ± 4 
 
Diazepam-D5 
7-aminonitrazepam 5.7 0.996 5.0 - 500 8 12 -13 0.23 1.52 0.24 -13 ± 5 
 
0.11 0.71 -4 ± 6 
 
EDDP-D3 
Oxazepam 21.8 0.998 5.0 - 500 1 4 3 0.15 0.98 0.16 14 ± 2 
 
0.39 2.58 31 ± 1 
 
Oxazepam-D5 
Chlordiazepoxide 16.9 0.998 0.5 - 500 5 11 -11 0.05 0.33 0.10 -6 ± 7 
 
0.04 0.26 -26 ± 2 
 
Diazepam-D5 
           
 
           
Antidepressants  
          
 
           
Dosulepin 18.2 0.997 0.5 - 500 6 6 -5 0.09 0.62 0.09 8 ± 7 
 
0.14 0.90 70 ± 14 
 
LSD-D3 
Amitriptyline 19.5 0.996 0.5 - 250 9 14 -4 0.08 0.55 0.22 2 ± 6 
 
0.06 0.40 40 ± 18 
 
LSD-D3 
Nortriptyline 19.9 0.996 5.0 - 250 8 8 -3 0.11 0.76 0.09 18 ± 5 
 
0.11 0.74 54 ± 2 
 
LSD-D3 
Fluoxetine 20.3 0.997 5.0 - 250 37 48 2 0.10 0.68 1.84 -10 ± 6 
 
0.07 0.47 29 ± 0 
 
Fluoxetine-D6 
Norfluoxetine 20.5 0.997 5.0 - 500 35 52 -11 0.09 0.58 0.17 -47 ± 8 
 
0.03 0.19 -165 ± 15 
 
Fluoxetine-D6 
Venlafaxine 14.6 0.998 0.5 - 500 8 17 4 0.06 0.40 0.10 6 ± 11 
 
0.06 0.38 24 ± 0 
 
LSD-D3 
           
 
           
Dissociative anaesthetics 
        
 
           
Phencyclidine  13.8 0.996 0.5 - 250 5 5 10 0.02 0.06 0.09 -53 ± 23 
 
0.01 0.05 -88 ± 2 
 
PCP-D5 
Ketamine  9.9 0.999 0.5 - 500 1 2 5 0.02 0.08 0.06 22 ± 2 
 
0.03 0.12 40 ± 0 
 
Ketamine-D4 
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Norketamine  9.9 0.998 0.5 - 500 2 2 3 0.07 0.44 0.03 18 ± 2 
 
0.11 0.75 34 ± 1 
 
Ketamine-D4 
           
 
           
Other 
          
 
           
Methaqualone 20.2 0.996 0.5 - 200 5 7 -11 0.07 0.49 0.03 29 ± 7 
 
0.05 0.35 13 ± 4 
 
Methaqualone-D7 
Sildenafil 17.8 0.996 5.0 - 500 7 10 -3 0.39 0.78 0.19 -11 ± 4 
 
0.27 0.54 -2 ± 3 
 
PCP-D5 
           
 
           
Drug precursors 
          
 
           
Ephedrine 4.9 0.998 0.5 - 500 3 2 13 0.27 0.54 0.20 -33 ± 16 
 
0.32 0.64 -123 ± 3 
 
Amphetamine-D11 
Norephedrine 4.0 0.997 5.0 - 500 4 14 0 0.20 0.99 0.49 -212 ± 47   0.47 2.36 -363 ± 7 
 
Amphetamine-D11 
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Table 2. Absolute SPE, PLE and PLE-SPE-LC-MS/MS recovery, and relative recovery for all analytes 
Compound 
Absolute and relative recovery (50 ng g
-1
)                                     
 
Soil 
 
Suspended particulate matter 
  
PLE                 
absolute rec. (%)
a
 
SPE                    
absolute rec. (%)
b
 
PLE-SPE-LC-MS/MS 
absolute rec. (%)
c
 
PLE-SPE-LC-MS/MS 
Relative rec. (%)
d
 
  
PLE                
absolute rec. (%)
a
 
SPE                 
absolute rec. (%)
b
 
PLE-SPE-LC-MS/MS 
absolute rec. (%)
c
 
PLE-SPE-LC-MS/MS 
Relative rec.(%)
d
 
Stimulants 
                         
Cocaine 87 ± 8 90 ± 8 78 ± 7 94 ± 6 
 
88 ± 4 92 ± 4 81 ± 4 93 ± 7 
Benzoylecgonine 91 ± 3 88 ± 9 80 ± 3 95 ± 2 
 
91 ± 5 66 ± 5 60 ± 3 97 ± 8 
Norbenzoylecgonine 91 ± 3 80 ± 7 73 ± 2 87 ± 2 
 
87 ± 2 80 ± 1 70 ± 1 113 ± 17 
Norcocaine 91 ± 6 85 ± 5 77 ± 5 93 ± 3 
 
86 ± 3 89 ± 2 77 ± 3 89 ± 6 
Cocaethylene 88 ± 6 88 ± 6 77 ± 5 92 ± 5 
 
91 ± 4 92 ± 1 84 ± 3 89 ± 6 
Anhydroecgonine M. E. 86 ± 4 49 ± 8 42 ± 2 51 ± 4 
 
68 ± 6 15 ± 0 10 ± 1 11 ± 1 
Ecgonidine  72 ± 13 16 ± 1 11 ± 2 13 ± 3 
 
77 ± 14 5 ± 0 4 ± 1 7 ± 0 
Amphetamine   90 ± 8 93 ± 9 84 ± 8 109 ± 3 
 
74 ± 2 69 ± 8 51 ± 1 94 ± 10 
Methamphetamine  90 ± 9 84 ± 7 76 ± 7 109 ± 7 
 
78 ± 5 73 ± 12 57 ± 3 85 ± 9 
Methcathinone 88 ± 8 69 ± 9 61 ± 5 87 ± 8 
 
50 ± 2 28 ± 6 14 ± 1 20 ± 0 
BZP 35 ± 5 50 ± 4 17 ± 3 32 ± 4 
 
56 ± 11 67 ± 4 37 ± 7 55 ± 9 
TFMPP 90 ± 13 68 ± 9 61 ± 9 115 ± 17 
 
81 ± 4 79 ± 5 64 ± 3 94 ± 7 
                          
Hallucinogens 
                         
MDA  88 ± 7 84 ± 9 73 ± 6 101 ± 7 
 
77 ± 1 71 ± 15 55 ± 1 82 ± 6 
MDMA 88 ± 6 76 ± 5 67 ± 5 114 ± 3 
 
81 ± 4 78 ± 9 63 ± 3 95 ± 6 
MDEA 92 ± 5 77 ± 6 71 ± 4 106 ± 3 
 
87 ± 5 83 ± 9 72 ± 4 95 ± 5 
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MBDB 90 ± 3 80 ± 6 72 ± 3 96 ± 2 
 
88 ± 5 85 ± 1 74 ± 5 92 ± 8 
BDB 86 ± 7 83 ± 8 72 ± 5 95 ± 5 
 
81 ± 5 89 ± 8 72 ± 5 88 ± 8 
Mescaline 92 ± 9 85 ± 7 78 ± 8 93 ± 6 
 
58 ± 5 103 ± 35 60 ± 5 91 ± 1 
LSD 81 ± 10 64 ± 7 52 ± 6 104 ± 11 
 
86 ± 4 89 ± 4 76 ± 4 90 ± 8 
O-H-LSD 88 ± 6 66 ± 5 58 ± 4 116 ± 8 
 
83 ± 6 66 ± 0 55 ± 4 65 ± 3 
                          
Opiods and morphine derivatives 
                      
Heroin 85 ± 7 68 ± 7 58 ± 5 93 ± 4 
 
84 ± 2 67 ± 2 56 ± 2 89 ± 7 
6-acetylmorphine 77 ± 9 104 ± 7 80 ± 10 94 ± 9 
 
90 ± 4 78 ± 5 70 ± 3 106 ± 21 
Codeine 89 ± 6 95 ± 8 85 ± 5 100 ± 5 
 
91 ± 5 77 ± 2 70 ± 4 105 ± 19 
Norcodeine 90 ± 6 90 ± 5 81 ± 6 95 ± 4 
 
83 ± 2 73 ± 4 61 ± 2 92 ± 20 
Oxycodone 84 ± 7 86 ± 10 72 ± 6 91 ± 5 
 
78 ± 0 52 ± 3 40 ± 0 91 ± 6 
Oxymorphone 89 ± 8 75 ± 12 67 ± 6 84 ± 7 
 
56 ± 6 30 ± 3 17 ± 2 38 ± 1 
Morphine 72 ± 10 94 ± 8 67 ± 9 99 ± 15 
 
78 ± 13 49 ± 5 38 ± 7 122 ± 7 
Normorphine 67 ± 8 92 ± 11 61 ± 8 90 ± 13 
 
75 ± 13 43 ± 6 32 ± 6 103 ± 6 
Dihydrocodeine 88 ± 6 89 ± 8 78 ± 6 97 ± 3 
 
83 ± 10 53 ± 5 44 ± 5 113 ± 9 
Buprenorphine 69 ± 9 69 ± 12 47 ± 6 114 ± 17 
 
84 ± 2 91 ± 0 76 ± 2 91 ± 10 
Norbuprenorphine 69 ± 9 76 ± 11 53 ± 7 127 ± 20 
 
84 ± 3 87 ± 0 73 ± 2 88 ± 11 
Methadone 107 ± 17 71 ± 10 76 ± 12 113 ± 18 
 
96 ± 4 94 ± 9 91 ± 3 115 ± 7 
EDDP 87 ± 18 40 ± 5 34 ± 7 97 ± 12 
 
91 ± 11 83 ± 9 75 ± 9 142 ± 14 
EMDP 84 ± 12 55 ± 14 47 ± 7 69 ± 10 
 
76 ± 4 82 ± 1 62 ± 3 79 ± 5 
Fentanyl 38 ± 6 70 ± 7 27 ± 4 110 ± 33 
 
89 ± 5 87 ± 3 78 ± 4 94 ± 4 
Norfentanyl 83 ± 7 87 ± 9 72 ± 6 89 ± 5 
 
79 ± 8 69 ± 3 55 ± 6 140 ± 13 
Propoxyphene  97 ± 9 80 ± 9 78 ± 7 103 ± 8 
 
84 ± 1 82 ± 5 69 ± 1 90 ± 8 
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Norpropoxyphene 109 ± 15 56 ± 6 61 ± 8 145 ± 23 
 
76 ± 7 91 ± 3 69 ± 6 94 ± 6 
Tramadol 92 ± 3 89 ± 6 82 ± 3 97 ± 2 
 
80 ± 16 95 ± 4 76 ± 15 112 ± 6 
Nortramadol 91 ± 8 84 ± 8 76 ± 7 90 ± 9 
 
72 ± 2 94 ± 28 68 ± 2 103 ± 22 
                          
Benzodiazepines 
                         
Temazepam 91 ± 5 14 ± 1 12 ± 1 101 ± 5 
 
86 ± 7 7 ± 1 6 ± 0 72 ± 10 
Diazepam  91 ± 3 84 ± 5 77 ± 2 97 ± 2 
 
81 ± 2 81 ± 7 66 ± 1 94 ± 10 
Nordiazepam  81 ± 4 82 ± 6 67 ± 4 85 ± 4 
 
74 ± 10 78 ± 8 58 ± 8 83 ± 21 
Nitrazepam 81 ± 4 64 ± 8 52 ± 2 66 ± 3 
 
84 ± 4 53 ± 4 44 ± 2 63 ± 5 
7-aminonitrazepam 54 ± 8 27 ± 6 15 ± 2 41 ± 5 
 
75 ± 0 45 ± 3 34 ± 0 64 ± 2 
Oxazepam 85 ± 5 35 ± 4 30 ± 2 94 ± 2 
 
80 ± 9 18 ± 3 14 ± 2 64 ± 1 
Chlordiazepoxide 83 ± 5 86 ± 8 72 ± 4 91 ± 5 
 
87 ± 3 89 ± 3 77 ± 3 110 ± 17 
                          
Antidepressants  
                         
Dosulepin 108 ± 7 51 ± 9 44 ± 25 109 ± 4 
 
108 ± 1 87 ± 10 93 ± 1 110 ± 5 
Amitriptyline 123 ± 11 47 ± 9 46 ± 26 115 ± 7 
 
108 ± 2 98 ± 16 106 ± 2 125 ± 6 
Nortriptyline 127 ± 14 39 ± 8 40 ± 23 100 ± 8 
 
119 ± 8 62 ± 1 74 ± 5 87 ± 3 
Fluoxetine 123 ± 17 34 ± 7 34 ± 19 127 ± 13 
 
106 ± 15 71 ± 9 75 ± 11 115 ± 20 
Norfluoxetine 130 ± 21 28 ± 7 29 ± 17 110 ± 14 
 
91 ± 17 54 ± 9 50 ± 9 75 ± 10 
Venlafaxine 75 ± 9 89 ± 9 67 ± 8 133 ± 13 
 
91 ± 3 95 ± 2 86 ± 3 102 ± 7 
                          
Dissociative anaesthetics 
                         
Phencyclidine  62 ± 10 86 ± 8 53 ± 8 99 ± 12 
 
75 ± 5 78 ± 10 58 ± 4 86 ± 8 
Ketamine  90 ± 4 87 ± 7 78 ± 4 95 ± 3 
 
92 ± 0 76 ± 4 70 ± 0 94 ± 6 
Norketamine  91 ± 5 75 ± 6 68 ± 4 83 ± 3 
 
85 ± 2 60 ± 6 51 ± 1 68 ± 3 
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Other 
                         
Methaqualone 96 ± 7 75 ± 11 72 ± 5 89 ± 5 
 
92 ± 4 89 ± 2 81 ± 3 94 ± 8 
Sildenafil 94 ± 16 61 ± 14 58 ± 10 115 ± 18 
 
98 ± 0 92 ± 5 90 ± 0 106 ± 4 
                          
Drug precursors 
                         
Ephedrine 92 ± 7 76 ± 10 70 ± 5 92 ± 5 
 
66 ± 1 53 ± 2 35 ± 1 64 ± 7 
Norephedrine 92 ± 7 89 ± 18 81 ± 6 106 ± 5   56 ± 8 41 ± 1 23 ± 3 42 ± 0 
a Absolute recovery for PLE; Soil (n = 5)/SPM (n = 2) spiked before PLE and compared to soil/SPM sample spiked after PLE (before SPE) 
b Absolute recovery for SPE (including evaporation and reconstitution); Soil (n = 3)/SPM (n = 2) spiked after PLE (before SPE) and compared to soil/SPM sample spiked during reconstitution 
c Absolute recovery for PLE-SPE-LC-MS/MS; Soil (n = 3)/SPM (n = 2) spiked before PLE in comparison to soil sample spiked during reconstitution 
d Relative to surrogate/internal standard; same samples as described in c 
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Table 3. Concentration of analytes sorbed onto suspended particulate matter (ng g
-1
), dissolved in wastewater (ng L
-1
) and the percentage of the total concentration determined 
on suspended particulate matter. Standard deviations in relation to the mean values shown in this table are listed in table S7. 
Compound 
October   November  
 
WWTP A   WWTP B   WWTP C 
 
WWTP A   WWTP B   WWTP C 
 
0.34 mg SPM per Litre 
 
0.31 mg SPM per Litre 
 
0.40 mg SPM per Litre 
 
0.29 mg SPM per Litre 
 
0.36 mg SPM per Litre   0.31 mg SPM per Litre 
 
SPM
a
 WW
b
 %
c
 
 
SPM
a
 WW
b
 %
c
 
 
SPM
a
 WW
b
 %
c
 
 
SPM
a
 WW
b
 %
c
 
 
SPM
a
 WW
b
 %
c
 
 
SPM
a
 WW
b
 %
c
 
Stimulants 
   
  
       
  
           
Cocaine 1.8 43.2 1.4 
 
2.6 43.9 1.8 
 
2.7 81.9 1.3 
 
1.8 37.5 1.3 
 
2.1 51.5 1.5 
 
2.0 66.7 0.9 
Benzoylecgonine 0.8 192.8 0.1 
 
1.1 172.6 0.2 
 
0.1 205.1 0.0 
 
0.9 140.9 0.2 
 
1.0 242.2 0.2 
 
0.1 154.9 0.0 
Norbenzoylecgonine ND 5.4 - 
 
ND 5.0 - 
 
ND 6.3 - 
 
ND 4.6 - 
 
ND 7.6 - 
 
ND 4.3 - 
Norcocaine ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Cocaethylene <MQL 1.4 - 
 
ND 1.1 - 
 
0.2 5.6 1.4 
 
ND 1.3 - 
 
ND 1.8 - 
 
0.3 3.5 2.2 
Anhydroecgonine M.E. ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Ecgonidine  ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Amphetamine
d
 5.2 46.0 3.7 
 
13.1 42.7 8.6 
 
5.2 124.7 1.6 
 
ND 48.3 - 
 
ND 116.4 - 
 
17.0 255.5 2.0 
Methamphetamine  ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND 0.6 - 
Methcathinone ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
BZP ND 36.1 - 
 
ND 21.3 - 
 
ND 21.3 - 
 
24.3 55.6 11.2 
 
ND ND - 
 
ND ND - 
TFMPP
d
 0.3 <MQL - 
 
ND 1.3 - 
 
2.0 8.8 8.1 
 
ND ND - 
 
ND 3.6 - 
 
0.7 2.2 8.3 
                        
Hallucinogens 
                       
MDA  ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
MDMA ND 1.8 - 
 
ND 2.3 - 
 
0.7 10.6 2.4 
 
0.2 2.8 1.7 
 
ND 1.8 - 
 
0.5 12.6 1.2 
MDEA ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
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MBDB ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
BDB ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Mescaline ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
LSD ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
O-H-LSD ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
                        
Opiods and morphine derivatives 
                     
Heroin ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
6-acetylmorphine ND 5.9 - 
 
ND 5.9 - 
 
ND 21.6 - 
 
ND 4.5 - 
 
ND 3.6 - 
 
ND 7.3 - 
Codeine 98.3 955.7 3.3 
 
77.2 949.9 2.4 
 
240.0 2041.5 4.4 
 
128.1 667.0 5.2 
 
59.0 1101.9 1.9 
 
130.0 1075.2 3.6 
Norcodeine 5.7 52.7 3.5 
 
ND 50.0 - 
 
10.3 96.7 4.0 
 
7.2 45.2 4.4 
 
ND 60.3 - 
 
ND 61.7 - 
Oxycodone <MQL 10.2 - 
 
<MQL 6.2 - 
 
<MQL 8.8 - 
 
<MQL 8.0 - 
 
<MQL 24.2 - 
 
<MQL 14.5 - 
Oxymorphone <MQL <MQL - 
 
ND <MQL - 
 
<MQL 17.4 - 
 
ND <MQL - 
 
ND <MQL - 
 
ND ND - 
Morphine 33.2 335.0 3.2 
 
22.7 337.0 2.0 
 
115.8 777.9 5.6 
 
25.3 156.4 4.4 
 
18.6 239.7 2.7 
 
33.1 274.3 3.6 
Normorphine 11.9 133.6 2.9 
 
ND 122.5 - 
 
15.7 201.0 3.0 
 
12.9 106.2 3.4 
 
ND 115.2 - 
 
16.4 147.4 3.3 
Dihydrocodeine 13.3 247.1 1.8 
 
13.2 276.3 1.4 
 
30.3 320.6 3.6 
 
11.9 126.9 2.6 
 
10.3 226.5 1.6 
 
16.1 239.5 2.1 
Buprenorphine 1.0 ND - 
 
ND ND - 
 
3.0 ND - 
 
ND ND - 
 
ND ND - 
 
1.4 ND - 
Norbuprenorphine ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Methadone 31.5 69.4 13.2 
 
23.0 70.0 9.1 
 
57.6 99.6 18.6 
 
24.3 69.1 9.2 
 
19.4 80.1 8.1 
 
41.0 104.8 10.9 
EDDP 61.9 126.3 14.1 
 
56.6 122.0 12.4 
 
194.0 145.9 34.5 
 
30.1 59.7 12.7 
 
55.1 144.5 12.1 
 
144.7 134.1 25.2 
EMDP 0.7 ND - 
 
0.3 <MQL - 
 
2.3 1.9 32.1 
 
0.2 ND - 
 
0.3 <MQL - 
 
1.3 1.2 26.2 
Fentanyl ND ND - 
 
ND ND - 
 
0.6 1.1 17.2 
 
ND ND - 
 
ND <MQL - 
 
ND <MQL - 
Norfentanyl ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Propoxyphene  ND ND - 
 
ND ND - 
 
ND <MQL - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
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Norpropoxyphene 48.8 203.1 7.5 
 
51.6 76.6 17.0 
 
133.9 274.7 16.2 
 
53.7 280.6 5.2 
 
15.2 154.8 3.4 
 
59.6 151.8 10.9 
Tramadol 109.3 1039.0 3.4 
 
116.0 1095.8 3.1 
 
199.2 1839.2 4.1 
 
43.3 841.4 1.5 
 
120.4 1327.0 3.2 
 
435.2 2758.7 4.7 
Nortramadol 61.9 335.5 5.8 
 
121.6 256.7 12.6 
 
206.3 616.3 11.7 
 
9.8 248.5 1.1 
 
196.1 830.7 7.9 
 
383.8 946.1 11.2 
                        
Benzodiazepines 
                      
Temazepam 2.2 77.5 0.9 
 
4.0 100.7 1.2 
 
ND 64.2 - 
 
5.9 63.8 2.6 
 
2.1 81.4 0.9 
 
ND 43.8 - 
Diazepam  ND <MQL - 
 
ND <MQL - 
 
ND <MQL - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Nordiazepam  ND 26.8 - 
 
ND 16.1 - 
 
ND 12.3 - 
 
ND 17.8 - 
 
ND 36.8 - 
 
ND 17.6 - 
Nitrazepam ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
7-aminonitrazepam 2.6 ND - 
 
ND ND - 
 
1.0 ND - 
 
1.3 ND - 
 
ND ND - 
 
1.6 ND - 
Oxazepam <MQL 18.7 - 
 
ND 23.0 - 
 
5.9 52.2 4.3 
 
<MQL 12.4 - 
 
ND 18.8 - 
 
4.2 27.8 4.5 
Chlordiazepoxide ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
                        
Antidepressants  
                       
Dosulepin 174.2 90.7 39.2 
 
73.0 87.9 20.2 
 
299.1 64.7 64.7 
 
128.7 155.2 19.3 
 
81.1 138.7 17.4 
 
179.9 81.8 40.7 
Amitriptyline 325.2 341.7 24.2 
 
118.3 347.2 9.4 
 
476.2 186.2 50.3 
 
180.2 201.9 20.4 
 
125.9 295.8 13.3 
 
629.2 741.1 20.9 
Nortriptyline 18.4 25.0 19.8 
 
3.7 30.7 3.6 
 
37.6 22.6 39.7 
 
9.4 38.6 6.5 
 
6.9 41.9 5.6 
 
30.4 30.9 23.5 
Fluoxetine 109.6 25.5 59.1 
 
77.5 26.8 46.8 
 
197.1 27.6 73.9 
 
72.1 32.1 39.2 
 
89.7 32.7 49.8 
 
199.2 40.2 60.7 
Norfluoxetine 54.6 12.4 59.6 
 
37.7 8.6 57.3 
 
87.1 4.1 89.4 
 
35.0 17.4 36.7 
 
53.4 25.2 43.4 
 
71.7 18.6 54.6 
Venlafaxine 4.2 87.9 1.6 
 
6.9 97.6 2.1 
 
15.3 149.7 3.9 
 
2.9 138.6 0.6 
 
3.6 134.9 1.0 
 
5.9 178.2 1.0 
                        
Dissociative anaesthetics 
                      
Phencyclidine  ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Ketamine  5.3 62.7 2.8 
 
1.5 85.5 0.5 
 
3.3 81.9 1.6 
 
1.9 45.7 1.2 
 
1.0 56.6 0.6 
 
7.2 349.4 0.6 
Norketamine  ND 6.2 - 
 
ND <MQL - 
 
ND 16.2 - 
 
ND <MQL - 
 
ND 5.3 - 
 
ND 20.1 - 
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Other 
                       
Methaqualone ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
 
ND ND - 
Sildenafil 10.0 18.1 15.7 
 
5.7 14.3 10.8 
 
14.8 39.1 13.0 
 
8.1 9.2 20.2 
 
12.1 22.3 16.4 
 
10.5 17.2 16.0 
                        
Drug precursors 
                       
Ephedrine ND 800.2 - 
 
ND 1079.5 - 
 
ND 1071.0 - 
 
ND 501.0 - 
 
ND 676.2 - 
 
ND 529.1 - 
Norephedrine ND ND -   ND ND -   ND ND -   ND ND -   ND ND -   ND ND - 
a Concentration of analyte on suspended particulate matter (ng g-1) (n = 2) 
b Concentration of analyte in wastewater (ng L-1) (n = 2) 
c Proportion of analyte on suspended particulate matter (n = 2) 
d MS ion ratio in all samples was outside the permitted tolerance range; therefore could not be reliably quantified. Nevertheless results are shown for information purposes 
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Figure S1 – Negative (a) and positive (b) effect on recovery with an increase in PLE extraction temperature
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Figure S2 – Cumulative absolute recovery (%) obtained with successive PLE cycles 
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Figure S3 - UPLC-MS/MS chromatograms of suspended particulate matter spiked with a concentration of 50 ng g-1 of each compound 
before PLE 
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Table S1 – Main parameters reported in analytical methods for the extraction drugs of abuse and pharmaceuticals in environmental solids  
No. of 
analytes 
Sample 
matrix 
(sample 
size) 
  
Pre-treatment and storage 
  
PLE conditions Spiking 
  
Absolute/relative 
recovery  
Post-treatment 
  
Reference 
  Cell matrix;                                    
Cell size 
Solvent Temp.;                                    
Pressure  
Cycles x 
static time  
Flush vol.;                                                      
Purge time  
1a Sewage 
sludge (1 
g) 
Centrifugation and Karl-Fischer 
titration                                                        
Sludge sonicated in 20 mL of 50 mM 
formic acid/MeOH (80/20, v/v)  
N/A N/A N/A N/A N/A NR NR Sonicated sample made 
up to 500 mL with H2O;                        
SPE - Oasis HLB (500 mg) 
(pH 10) 
Kaleta et al. [1] 
10b  Sewage 
sludge (5 
g) 
Samples stored in the freezer until 
analysis                                                       
Sludge lyophilised, pestle and 
mortared and sieved (< 125 µm) 
Aluminium 
oxide;                           
33 mL 
extraction cell 
50 mM 
phosphoric 
acid/MeOH 
(50/50, v/v) 
100 °C;                                            
1450 psi 
2 x 15 min 150 %;                             
300 sec 
Spiked directly onto 
freeze dried sludge 
and stirred 
intensively 
Absolute recoveryc: 
70 – 120% (9/10)                                  
68% (1/10)                       
 
PLE extract (approx. 40 
mL) filtered (0.45 µm 
microfilter) and analysed 
by LC 
Nieto et al. [2] 
27d Sewage 
sludge (1 
g) 
Samples  stored at -5 °C until analysis                                                                      
Soil/sludge lyophilised and sieved 
(<0.7 mm) 
Sea sand;
33 mL 
extraction cell 
MeOH/H2O
(50/50, v/v) 
60 °C;                                                          
1500 psi 
2 x 5 min 100 %;                                                                       
60 sec 
Spiking carried out
directly onto 
soil/sludge 
Absolute recoverye,f:                   
70 - >130% (16/24)                              
40 – 65% (7/24)                                       
2% (1/24)                                        
PLE extract (approx.53 mL) 
made up to 1 L with H2O;                           
SPE - Oasis HLB (200 mg) 
(pH 5.5)  
Barron et al. [3] 
Soil (2.7 g) Absolute recoverye:          
70 - >130% (18/27)                                                                  
50 - 60% (4/27)                                                             
<30% (4/27) 
12g River 
sediments 
(1 g) 
Samples air dried and sieved (< 2 mm) Quartz sand;                           
11 mL 
extraction cell 
MeOH/H2O 
(50/50 v/v) 
100 °C;                                                    
1450 psi 
3 x 5 min 120 %;                                                                      
30 sec 
Analytes spiked
onto mixture of 
sediment and sand 
Absolute recoveryh: 
71 – 82% (6/12) 
43 – 61% (5/12) 
32% (1/12)                                 
Relative recovery:                            
96-134% (12/12) 
PLE extract (approx. 35 
mL) made up to approx. 
615 mL with ground 
water;                            SPE 
- Oasis HLB (200 mg) (pH 
7) 
Stein et al. [4] 
31i Sewage 
sludge (1 
g) 
Centrifugation and lyophilisation                              
Stored at -40 °C until analysis 
Hydromatrix;                           
11 mL 
extraction cell 
MeOH/H2O 
(1/2, v/v) 
100 °C;                                                         
1500 psi 
3 x 5 min 100 %;                                                                    
60 sec 
Freeze dried sludge
samples spiked and 
then stirred 
intensively for 24 hr 
Absolute recoveryj:                      
70 – 124% (12/31)                                  
44 – 69% (13/31)                     
<30% (6/31) 
PLE extract (approx. 22 
mL) made up to 500 mL;                                   
SPE - Oasis HLB (200 mg) 
Radjenović et al. [5] 
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17k  Sediment 
(3 g) 
Sediment samples were lyophilised, 
sieved (< 2 mm) and homogenised                                               
Samples stored at -20 °C 
Sea sand;                           
22 mL
extraction cell 
H2O 90 °C;                                                      
500 psi 
3 x 7 min 100 %;                                                                         
60 sec 
Soil/sediment
spiked and stirred 
for 30 min. Samples  
then equilibrated 
for 24 h  
Absolute recoveryl:                  
70 – 95% (12/17)                                
48 – 64% (4/17)                       
37% (1/17)                                
Relative recovery                      
65 – 104% (17/17)                               
PLE extract (approx. 30 
mL);                                 
SPE - Isolute SAX (500 mg) 
placed on top of an Oasis 
HLB (60 mg) 
Vasquez-Roig et al. [6] 
Soil (3 g) Soil samples were air dried in the dark 
at 20 °C, sieved (< 2 mm) and 
homogenised                                            
Samples stored at 4 °C 
Absolute recoveryl:                  
74 – 104% (10/17)                                 
41 –64% (6/17)                                      
37% (1/17)                                
Relative recovery                      
67 – 108% (17/17)      
6m  SPMn Waste water filtered through glass-
fibre filters and filters lyophilised                                                          
Frozen until analysis                  Filters 
sonicated in 100 mL  50 mM formic 
acid/MeOH (80/20, v/v) (repeated 
twice) 
N/A N/A N/A N/A N/A Analytes spiked on 
to 70 glass fibre 
filters 
Absolute recoveryo:                
70 – 87% (6/6) 
Sonicated sample made 
up to 2100 mL;                                    
SPE - Oasis MCX (pH 3) 
Metcalfe et al. [7] 
N.R. = not reported in manuscript; N/A = not applicable as PLE was not used in the analytical method; a Amphetamine; b 10 pharmaceuticals; c It is not clear in the manuscript how recoveries were calculated, although it would seem that spiked 
sludge was compared to spiked diluent; d 27 pharmaceuticals; e Recoveries calculated by spiking soil/sludge before PLE and comparing against blank soil/sludge spiked during reconstitution; f Recoveries for three compounds could not be calculated 
in sewage sludge; g 12 pharmaceuticals; h Absolute recoveries calculated by spiking sediment prior to PLE and comparing the peak area to a standard solution without matrix; I 31 pharmaceuticals; j Recoveries were determined through pre- and post 
spiking of matrix. However, it is not clear in this manuscript if recoveries were absolute or relative, and if they refer to only the PLE step or both PLE and SPE; k 17 pharmaceuticals; l Absolute recovery calculated by spiking soil and sediment before 
PLE and relates to the entire extraction process, although it is unclear if this value includes matrix effects; m 6 drugs of abuse; n Particulate matter on filters used for testing, but dry weight of SPM not reported; o Recovery calculated by spiking filters 
without matrix before USE, and comparing to standard solution 
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Table S2 - Selected analytes and their properties 
Compound CAS Formula MW Pka  LogP LogDb  Supplier 
        Exp.a Calc.b Exp.a Calc.b pH 7 pH 8  
Stimulants and their metabolites 
         
Cocaine 50-36-2 C17H21NO4 303.4 8.6 (20°) 8.9 2.3 2.3 0.3 1.3 LGC 
Benzoylecgonine 519-09-5 C16H19NO4 289.3 - 10.8, 3.3 -1.3 2.3 -0.2 -0.2 LGC 
Norbenzoylecgonine 60426-41-7 C15H17NO4 275.3 - 10.4, 3.4 - 2.6 0.1 0.1 LGC 
Norcocaine - C16H19NO4 289.3 - 9.0 - 3.1 1.1 2.1 LGC 
Cocaethylene 529-38-4 C18H23NO4 317.4 - 9.0 - 2.8 0.8 1.7 LGC 
Anhydroecgonine  
methyl ester 
43021-26-7 C10H15NO2 181.2 - 8.0 - 0.4 0.1 -0.6 LGC 
Ecgonidine  74242-55-0 C8H11NO2 153.2 - 9.6, 3.8 - 1.5 -1 -1 LGC 
Amphetamine   300-62-9             C9H13N 135.2 10.1 9.9 1.8 1.8 -0.9 -0.1 LGC 
Methamphetamine  
R-(-):33817-09-3, 
S-(+):537-46-2       
C10H15N 149.2 10.1 10.4 2.1 2.2 -0.7 -0.1 LGC 
Methcathinone 49656-78-2 C10H13NO 163.2 - 7.1 - 0.4 0 0.3 
Sigma-
Aldrich 
BZP - C11H16N2 176.3 - 9.3, 3.4 - 1.1 -1 -0.1 LGC 
TFMPP - C11H13F3N2 230.2 - 8.8, 2.1 - 1.3 0.7 -0.2 LGC 
           
Hallucinogens and their metabolites 
         
MDA  4764-17-4 C10H13NO2 179.2 - 9.9 1.64 1.6 -1.1 -0.3 LGC 
MDMA 4254210-9 C11H15NO2 193.2 
(benzene, 
pH 9.0) 9.4 
10.3 - 2.1 -0.8 -0.2 LGC 
MDEA 82801-81-8 C12H17NO2 207.3 - 10.3 - 2.6 -0.3 0.3 LGC 
MBDB 145225-00-9 C12H17NO2 207.3 - 10.5 - 2.6 -0.4 0.2 LGC 
BDB - C11H15NO2 193.2 - 10 - 2.2 -0.6 0.2 LGC 
Mescaline 832-92-8 C11H17NO3 211.3 9.6 9.6 0.8 0.5 -1.9 -1 LGC 
LSD 50-37-3 C20H25N3O 323.4 7.5 7.4 2.9 2.7 2.1 2.6 LGC 
O-H-LSD - C20H25N3O3 355.4 - 11.7, 6.8 - -1.9 -2.1 -1.9 LGC 
           
Human indicators 
          
Caffeine 58-08-2 C8H10N4O2 194.2 
14.0 (25°), 
10.4 (40°) 
0.5  -0.07 -0.6 -0.6 -0.6 
Sigma-
Aldrich 
1,7-dimethylxanthine 611-59-6 C7H8N4O2 180.2 - 8.5, 0.2  - -0.9 -1 -1.1 
Sigma-
Aldrich 
Nicotine 54-11-5 C10H14N2 162.2 
7.9, 3.2, 
(25°) 
8.0, 3.2   1.2 0.6 -1 -0.1 
Sigma-
Aldrich 
Continine 486-56-6 C10H12N2O 176.2 - 4.7 - 0.07 0.1 0.1 
Sigma-
Aldrich 
           
Opioids, morphine derivatives and their 
metabolites          
Heroin 561-27-3 C21H23NO5 369.4 7.6 (23°) 7.9 1.58 1.6 0.6 1.3 LGC 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4 - 9.4, 8.0 - 1.6 0.6 1.3 LGC 
Codeine 76-57-3 C18H21NO3 299.4 8.2 (20°) 13.4, 8.2 0.6 1.4 0.1 0.9 
Sigma-
Aldrich 
Norcodeine 467-15-2 C17H19NO3 285.3 9.2 (25°) 13.3, 9.3 0.7 0.5 -1.8 -0.9 LGC 
Oxycodone 76-42-6 C18H21NO4 315.4 8.9 (20°) 13.1, 7.6 0.7 1.6 0.8 1.4 LGC 
Oxymorphone 76-41-5 C17H19NO4 301.3 9.3, 8.5  13.5, 9.2, 7.6 0 1.2 0.5 1 LGC 
Morphine 57-27-2 C17H19NO3 285.3 
9.9, 8.0 
(20°) 
13.5, 9.5, 8.3 -0.1 0.9 -0.3 0.5 LGC 
Normorphine 466-97-7 C16H17NO3 271.3 9.8 (25°) 13.4, 9.5, 9.2 -2.8 0 -2.3 -1.4 LGC 
Dihydrocodeine 125-28-0 C18H23NO3 301.4 8.8 (25°) 8.4 - 0.6 -0.9 0 LGC 
Buprenorphine 52485-79-7 C29H41NO4 467.6 8.5, 10.0 9.5, 8.3 5 2.8 1.5 2.3 LGC 
Norbuprenorphine 78715-23-8 C25H35NO4 413.6 - 9.8, 9.1 - 1.2 -1.2 -0.4 LGC 
Methadone 76-99-3 C21H27NO 309.4 
8.94 (25°), 
8.3 (20°)  
9.1 3.9 3.9 1.9 2.8 
Sigma-
Aldrich 
EDDP 66729-78-0 C21H25N 291.4 - 8.4 - 5 3.7 4.5 LGC 
EMDP - C20H23N 277.4 - 8.1 - 5.8 4.7 5.4 LGC 
Fentanyl 437-38-7 C22H28N2O 336.5 - 8.9, 0.3 2.3 3.7 2.2 3.1 LGC 
Norfentanyl - C14H20N2O 232.3 - 9.8, 0.3 - 1.7 -0.8 0.1 LGC 
Propoxyphene  469-62-5 C22H29NO2 339.5 6.3 9.2 4.2 4.1 1.9 2.9 LGC 
Norpropoxyphene 159208-83-0 C21H27NO2 325.4 - 10.1 - 3.7 0.9 1.7 LGC 
Tramadol 36282-47-0 C16H25NO2 263.4 9.4, 8.3 9.6 3 2.3 -0.1 0.9 
Sigma-
Aldrich 
Nortramadol - C15H23NO2 249.4 - 10.6 - 1.7 -1.3 -0.7 LGC 
           
Benzodiazepines and their metabolites 
         
Temazepam 846-50-4 
C16H13ClN2O
2 
300.7 1.6 11.7, 1.6 2.2 2.2 2.2 2.2 LGC 
Diazepam 439-15-5 C16H13ClN2O 284.7 3.3 (20°) 3.4 2.7 2.8 2.8 2.8 LGC 
Nordiazepam  1088-11-5 C15H11ClN2O 270.7 12.0, 3.5  11.7, 3.2 2.9 2.8 2.8 2.8 LGC 
Nitrazepam 146-22-5 C15H11N3O3 281.3 
10.8, 3.2 
(20°) 
11.4, 2.6 2.1 2.4 2.4 2.4 
Sigma-
Aldrich 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3  
12.3, 4.3, 2.3 - 1.1 1.1 1.1 LGC 
Oxazepam 604-75-1 
C15H11ClN2O
2 
286.7 
11.6, 1.7 
(20°) 
12.8, 10.9, 1.2 2.2 2.2 2.2 2.2 LGC 
Chlordiazepoxide 58-25-3 C16H14ClN3O 299.8 4.8 8.6, 6.5 2.4 2.8 2.2 2.1 LGC 
           
Antidepressants and their metabolites 
         
Dosulepin 113-53-1 C19H21NS 295.4 - 9.1 2.8 4.3 2.2 3.1 LGC 
Amitriptyline 549-18-8 C20H23N 277.4 9.4 (25°) 9.2 5 4.4 2.3 3.2 
Sigma-
Aldrich 
Nortriptyline 894-71-3 C19H21N 263.4 9.7 10 1.7 4 1.2 2 
Sigma-
Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3 - 10.1 1.8 3.9 1.2 1.9 LGC 
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Norfluoxetine - C16H16F3NO 295.3 - 9.1 - 3.8 1.7 2.7 LGC 
Venlafaxine 99300-78-4 C17H27NO2 277.4 - 9.3 0.4 2.5 0.4 1.3 
Sigma-
Aldrich 
           
Dissociative anesthetics and their metabolites 
         
Phencyclidine 77-10-1 C17H25N 243.4 8.5 8.2 4.7 4.3 3 3.8 LGC 
Ketamine  1867-66-9 C13H16ClNO 237.7 7.5 6.5 3.1 3 2.9 3 
Sigma-
Aldrich 
Norketamine  - C12H14ClNO 223.7 6.7 6.3  
2.4 2.3 2.3 LGC 
           
Other 
          
Methaqualone 72-44-6 C16H14N2O 250.3 2.5 3 4.3 2.5 2.5 2.5 LGC 
Sildenafil 139755-83-23 C22H30N6O4S 474.6 8.7 6.0, 0.6  
1.6 1.6 1.6 LGC 
           
Drug precursors 
          
Ephedrine 50-98-6 C10H15NO 165.2 9.6 (25°) 9.5 1.1 1 -1.3 -0.4 LGC 
Norephedrine 154-41-6 C9H13NO 151.2  - 12.1, 8.5   0.4 -1.9 -1 
Sigma-
Aldrich 
a
 extracted from [8] 
b
 predicated using ACD labs software [9] 
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Table S3 - Optimized MRM conditions and ion ratios 
Compound CV/CEa MRM1 
(quantification) 
CV/CEa MRM2 
(confirmation) 
MRM ratiob ± % RSD 
Stimulants and their metabolites        
Cocaine 40/20 304.2 > 182.1 40/31 304.2 > 82.1 2.56 ± 0.04 
Benzoylecgonine 38/19 290.2 > 168.1 38/30 290.2 > 105.1 2.67 ± 0.04 
Norbenzoylecgonine 32/16 276.1 > 154.0 32/21 276.1 > 136.1 1.53 ± 0.03 
Norcocaine 40/15 290.2 > 168.1 40/24 290.1 > 136.1 1.76 ± 0.10 
Cocaethylene 38/20 318.2 > 196.2 38/30 318.2 > 82.1 1.68 ± 0.03 
Anhydroecgonine methyl ester 39/23 182.1 > 118.0 39/21 182.1 > 122.1 0.83 ± 0.09 
Ecgonidine  37/23 168.1 > 91.1 37/20 168.1 > 122.1 2.68 ± 0.22 
Amphetamine   18/8 136.2 > 119.1 18/16 136.2 > 91.1 4.55 ± 0.16 
Methamphetamine  24/19 150.2 > 91.1 24/10 150.2 > 119.1 2.82 ± 0.11 
Methcathinone 28/19 164.1 > 131.0 28/12 164.1 > 146.1 0.55 ± 0.03 
BZP 35/20 177.1 > 91.1 35/15 177.1 > 85.1 6.18 ± 0.11 
TFMPP 46/23 231.0 > 188.0 46/35 231.0 > 118.3 2.42 ± 0.06 
        
Hallucinogens and their metabolites        
MDA  21/11 180.0 > 163.1 21/22 180.0 > 105.1 3.05 ± 0.07 
MDMA 24/13 194.1 > 163.1 24/24 194.1 > 105.1 2.51 ± 0.08 
MDEA 28/13 208.1 > 163.1 28/27 208.1 > 105.1 3.18 ± 0.05 
MBDB 26/20 208.1 > 135.1 26/11 208.1 > 177.1 2.52 ± 0.14 
BDB 20/9 194.1 > 177.1 20/16 194.1 > 135.1 4.03 ± 0.51 
Mescaline 46/12 212.3 > 195.1 46/18 212.3 > 180.1 1.83 ± 0.15 
LSD 41/24 324.2 > 223.2 41/28 324.2 > 208.1 1.62 ± 0.04 
O-H-LSD 41/24 356.2 > 237.1 41/24 356.2 > 74.1 1.46 ± 0.04 
        
Human indicators        
Caffeine 38/15 195.1 > 138.0 38/23 195.1 > 110.0 2.93 ± 0.06 
1,7-dimethylxanthine 54/21 181.0 > 124.1 none none -  - 
Nicotine 37/20 163.1 > 130.0 37/24 163.1 > 117.0 0.95 ± 0.04 
Continine 34/21 177.1 > 80.0 34/22 177.1 > 98.1 3.15 ± 0.08 
Creatinine 31/11 114.0 > 86.1 31/16 114.0 > 72.1 2.54 ± 0.08 
        
Opioids, morphine derivatives and their metabolites       
Heroin 51/50 370.2 > 165.1 51/29 370.2 > 268.1 1.39 ± 0.04 
6-acetylmorphine 52/39 328.1 > 165.1 52/26 328.1 > 211.1 1.77 ± 0.04 
Codeine 49/57 300.2 > 152.1 49/25 300.2 > 215.1 1.22 ± 0.03 
Norcodeine 46/40 286.1 > 165.1 46/20 286.1 > 268.2 0.87 ± 0.03 
Oxycodone 36/29 316.2 > 241.1 36/26 316.2 > 256.1 1.46 ± 0.04 
Oxymorphone 40/19 302.1 > 284.1 40/28 302.1 > 227.1 3.59 ± 0.09 
Morphine 53/56 286.1 > 152.1 53/38 286.1 > 165.1 1.33 ± 0.05 
Normorphine 45/49 272.1 > 152.1 45/43 272.1 > 165.0 1.34 ± 0.03 
Dihydrocodeine 53/33 302.1 > 199.1 53/60 302.1 > 128.1 1.48 ± 0.04 
Buprenorphine 69/45 468.3 > 84.1 69/43 468.3 > 101.0 1.69 ± 0.04 
Norbuprenorphine 60/47 414.3 > 83.0 60/39 414.3 > 101.1 1.26 ± 0.03 
Methadone 31/15 310.2 > 265.1 31/28 310.2 > 105.1 2.26 ± 0.08 
EDDP 50/29 278.2 > 234.1 50/24 278.2 > 249.1 1.15 ± 0.11 
EMDP 47/21 264.2 > 235.1 47/31 264.2 > 220.2 1.04 ± 0.02 
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Fentanyl 44/38 337.2 > 105.1 44/23 337.2 > 188.2 1.01 ± 0.03 
Norfentanyl 27/20 233.2 > 84.0 27/15 233.2 > 177.1 17.68 ± 0.44 
Propoxyphene  19/8 340.2 > 266.2 19/22 340.2 > 143.0 24.40 ± 1.28 
Norpropoxyphene 15/7 326.2 > 252.1 none none -  - 
Tramadol 24/17 264.2 > 58.1 24/11 264.2 > 246.3 92.34 ± 3.07 
Nortramadol 21/8 250.2 > 232.1 none none - - - 
        
Benzodiazepines and their metabolites        
Temazepam 37/21 301.1 > 255.1 37/14 301.1 > 283.1 1.97 ± 0.07 
Diazepam  54/27 285.0 > 154.1 54/31 285.0 > 193.1 1.32 ± 0.02 
Nordiazepam  51/29 271.1 > 140.1 51/29 271.1 > 165.0 1.26 ± 0.06 
Nitrazepam 44/24 282.1 > 236.1 44/37 282.1 > 180.1 6.12 ± 0.29 
7-aminonitrazepam 48/25 252.1 > 121.1 48/40 252.1 > 94.1 3.05 ± 0.09 
Oxazepam 38/21 287.1 > 241.1 38/15 287.1 > 269.0 1.15 ± 0.04 
Chlordiazepoxide 32/15 300.1 > 283.1 32/25 300.1 > 227.1 2.04 ± 0.08 
        
Antidepressants and their metabolites        
Dosulepin 34/24 296.1 > 218.1 34/24 296.1 > 223.1 0.81 ± 0.02 
Amitriptyline 37/26 278.2 > 91.1 37/18 278.2 > 233.2 1.10 ± 0.02 
Nortriptyline 33/16 264.2 > 233.1 33/23 264.2 > 91.0 1.30 ± 0.03 
Fluoxetine 25/8 310.3 > 148.1 none none -  - 
Norfluoxetine 17/7 296.2 > 134.1 none none -  - 
Venlafaxine 27/12 278.2 > 260.1 27/32 278.2 > 121.0 3.93 ± 0.11 
        
Dissociative anaesthetics and their 
metabolites 
       
Phencyclidine  18/14 244.2 > 159.1 18/34 244.2 > 91.1 1.24 ± 0.03 
Ketamine  31/27 238.1 > 125.0 31/15 238.1 > 220.1 2.71 ± 0.04 
Norketamine  23/27 224.0 > 125.0 23/12 224.0 > 207.1 1.02 ± 0.03 
        
Other        
Methaqualone 58/27 251.1 > 132.1 58/42 251.1 > 91.1 5.53 ± 0.59 
Sildenafil 60/28 475.3 > 100.2 60/40 475.3 > 283.2 4.46 ± 0.07 
        
Drug precursors        
Ephedrine/Pseudoephedrine  23/12 166.1 > 148.1 23/21 166.1 > 133.0 43.37 ± 5.41 
Norephedrine 21/11 152.1 > 134.1 21/19 152.1 > 117.1 64.26 ± 7.56 
        
Internal standards        
Cocaine-D3 40/20 307.2 > 185.1      
Benzoylecgonine-D8 38/19 298.2 > 171.1      
Cocaethylene-D8 38/20 326.2 > 204.2      
Amphetamine-D11 18/8 147.2 > 130.1      
Methamphetamine-D14 24/19 164.2 > 98.1      
MDA-D5 21/11 185.1 > 168.1      
MDMA-D5 26/13 199.1 > 165.1      
MBDB-D5 26/20 213.1 > 136.1      
MDEA-D5 28/13 213.1 > 163.0      
Caffeine-D9 38/15 204.2 > 144.1      
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Nicotine-D4 37/20 167.1 > 134.1      
LSD-D3 41/24 327.2 > 226.1      
Heroin-D9 51/50 379.2 > 165.8      
Oxycodone-D6 36/29 322.2 > 247.1      
Morphine-D6 53/38 292.2 > 171.1      
Methadone-D9 31/15 319.3 > 268.2      
EDDP-D3 50/29 281.2 > 234.1      
Fentanyl-D5 44/38 342.2 > 105.1      
Codeine-D6 52/28 306.2 > 218.1      
Dihydrocodeine-D6 53/33 308.2 > 202.1      
Buprenorphine-D4 69/45 472.4 > 88.1      
Propoxyphene-D11 19/8 351.3 > 277.2      
Norpropoxyphene-D5 15/7 331.2 > 257.2      
Temazepam-D5 37/21 306.7 > 260.1      
Diazepam-D5 54/27 290.1 > 154.1      
Oxazepam-D5 38/21 292.0 > 246.0      
Fluoxetine-D6 25/8 316.2 > 154.1      
PCP-D5 18/14 249.2 > 164.1      
Ketamine-D4 31/27 242.1 > 129.1      
Mescaline-D9 46/12 221.2 > 204.2      
Methaqualone-D7 58/27 258.2 > 139.1           
aCV, cone voltage (V); CE, collision energy (eV) 
b MRM ratio : MRM1/MRM2 ratio calculated in surface water  
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Effect of sample methanol content on SPE recovery 
Initially, before optimising the PLE process, an investigation into the percentage of organic 
solvent that can be used before effecting SPE recoveries was undertaken. This parameter is of 
importance due to the need to dilute PLE extracts to reduce organic composition [3,5,10,11]. 
Dilution is generally performed so that organic content is around 5 % or less. However, doing 
so then results in increased times for SPE extraction. 
In this study the percentage of methanol in water was investigated at 25, 50 and 75 %. All 
analytes were spiked into 100 mL of methanol: water at 10 ng per analyte and extracted in 
duplicate according to the SPE procedure described in section 2.4. The recoveries for each 
analyte in the different solvents were normalised against the recovery generated from a 
completely aqueous sample. Results are shown in Table S4. 
The results show that a sample composition of 25 % methanol in relation to 0 % methanol 
leads to little effect on the vast majority of analytes, with a change of less than 10 % for 
nearly all compounds. However there were significant exceptions. Anhydroecgonine methyl 
ester and ecgonidine reported a decrease in recovery of 63 and 77 %, respectively. Similarly, 
a high decrease in recovery was observed for caffeine (94 %), 1,7-dimethylxanthine (94 %), 
nicotine (93 %) and continine (86 %). A percentage of methanol content of 50 and 75 % 
resulted in unacceptably decreased recoveries for nearly all compounds.  
Although a methanol composition of 25 % led to the significant decrease in the recovery of 
a small number of compounds, it was decided that the ability to use a much smaller dilution 
factor was more beneficial. In particular this was because the analytes in question, 
anhydroecgonine methyl ester and ecgonidine, had not been measured at > MDL in 
wastewater between the sampling months of December 2009 to November 2010. Therefore it 
was unlikely that either compound would be detected in SPM. Caffeine, 1,7-
dimethylxanthine, nicotine and continine were not further analysed due to low SPE recovery. 
The ability to use up to 25 % methanol in water when performing SPE with an Oasis MCX 
may provide an important advantage over methods which employ the Oasis HLB and need to 
dilute methanol content to < 5 %. For instance Jelic et al. [11] used a solvent of methanol/ 
water, 1/2 (v/v) and obtained a PLE extract of around 22 mL which was diluted to 500 mL 
and extracted using an Oasis HLB sorbent. With the SPE method in this study it may have 
been possible to dilute to a much smaller volume of around 60 mL. Similarly, Barron et al. 
[3] used a PLE solvent of methanol water, 1/1 (v/v) and obtained a PLE extract of around 53 
mL which was then diluted to 1000 mL and extracted with Oasis HLB sorbent. Using the 
SPE method in this study it may have been possible to dilute to just over 100 mL. These 
conclusions are of course speculative, and with a different set of compounds the recoveries 
obtained may have changed dramatically. Nevertheless, this shows that a mixed mode sorbent 
may provide significant improvements in reducing the dilution factor and in turn the time 
required for extraction. When selecting SPE sorbent, an evaluation of the effect of methanol 
content should be considered rather than simply the recovery of compounds in isolation. 
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Table S4 – SPE recovery with an increasing methanol to water sample composition 
Compound SPE recovery (n=2, 100ng L
-1
) 
 SPE recovery change (%)  in relation to 0:100 methanol:water     
  25:75   50:50   75:25 
Stimulants            
Cocaine -1 ± 1  -18 ± 1  -76 ± 1 
Benzoylecgonine 2 ± 1  -56 ± 0  -89 ± 0 
Norbenzoylecgonine 4 ± 3  -27 ± 1  -83 ± 0 
Norcocaine -3 ± 0  -10 ± 1  -65 ± 2 
Cocaethylene -1 ± 0  -12 ± 3  -76 ± 1 
Anhydroecgonine methyl ester -63 ± 9  -79 ± 2  -88 ± 3 
Ecgonidine  -77 ± 2  -89 ± 1  -90 ± 2 
Amphetamine   -3 ± 2  -9 ± 0  -63 ± 0 
Methamphetamine  -5 ± 3  -4 ± 7  -36 ± 5 
Methcathinone -17 ± 7  -37 ± 5  -77 ± 3 
BZP -3 ± 5  -15 ± 4  -14 ± 7 
TFMPP -2 ± 0  -9 ± 2  -12 ± 1 
            
Hallucinogens            
MDA  -1 ± 4  4 ± 5  2 ± 6 
MDMA -1 ± 3  18 ± 17  26 ± 16 
MDEA 1 ± 4  10 ± 7  12 ± 1 
MBDB 0 ± 6  -1 ± 9  -26 ± 4 
BDB 0 ± 5  -3 ± 3  -41 ± 1 
Mescaline 4 ± 5  -43 ± 3  -76 ± 0 
LSD -3 ± 1  -11 ± 6  -36 ± 2 
O-H-LSD -15 ± 4  -75 ± 1  -91 ± 0 
            
Human indicators            
Caffeine -94 ± 0  -97 ± 0  -98 ± 0 
1,7-dimethylxanthine -94 ± 1  -98 ± 0  -99 ± 0 
Nicotine -93 ± 1  -86 ± 7  -92 ± 0 
Continine -86 ± 4  -90 ± 2  -87 ± 5 
            
Opioids and morphine derivatives            
Heroin -3 ± 2  -37 ± 1  -80 ± 0 
6-acetylmorphine -3 ± 1  -54 ± 1  -80 ± 1 
Codeine 3 ± 6  -51 ± 1  -74 ± 0 
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Norcodeine 5 ± 2  -36 ± 4  -64 ± 0 
Oxycodone -5 ± 5  -59 ± 1  -83 ± 2 
Oxymorphone 2 ± 3  -74 ± 1  -82 ± 2 
Morphine -5 ± 6  -74 ± 0  -81 ± 3 
Normorphine -4 ± 4  -69 ± 3  -77 ± 2 
Dihydrocodeine 0 ± 5  -60 ± 0  -80 ± 0 
Buprenorphine 0 ± 1  -14 ± 13  -66 ± 3 
Norbuprenorphine -2 ± 0  -15 ± 4  -61 ± 3 
Methadone -2 ± 2  -14 ± 5  -60 ± 4 
EDDP 3 ± 5  6 ± 13  -17 ± 5 
EMDP -11 ± 7  15 ± 10  -44 ± 5 
Fentanyl -1 ± 0  -38 ± 2  -77 ± 1 
Norfentanyl 0 ± 1  -5 ± 2  -33 ± 2 
Propoxyphene  -2 ± 2  -20 ± 6  -66 ± 4 
Norpropoxyphene -6 ± 3  -28 ± 5  -51 ± 7 
Tramadol -2 ± 0  -32 ± 0  -80 ± 1 
Nortramadol -1 ± 8  -11 ± 1  -72 ± 1 
            
Benzodiazepines            
Temazepam 3 ± 6  -89 ± 0  -99 ± 0 
Diazepam  4 ± 4  -10 ± 1  -77 ± 2 
Nordiazepam  7 ± 5  -16 ± 1  -76 ± 1 
Nitrazepam -6 ± 1  -41 ± 4  -84 ± 2 
7-aminonitrazepam 0 ± 1  -18 ± 12  -18 ± 1 
Oxazepam -4 ± 0  -89 ± 1  -99 ± 0 
Chlordiazepoxide -4 ± 3  -26 ± 4  -54 ± 3 
            
Antidepressants             
Dosulepin 4 ± 4  -10 ± 13  -12 ± 1 
Amitriptyline -1 ± 0  -10 ± 6  -15 ± 2 
Nortriptyline 5 ± 8  4 ± 10  12 ± 19 
Fluoxetine 9 ± 1  1 ± 3  6 ± 8 
Norfluoxetine 7 ± 3  -1 ± 7  5 ± 5 
Venlafaxine 3 ± 1  -13 ± 2  -68 ± 1 
            
Dissociative anaesthetics            
Phencyclidine  -7 ± 1  -9 ± 4  -55 ± 1 
Ketamine  -6 ± 11  -38 ± 6  -83 ± 0 
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Norketamine  -8 ± 0  -61 ± 1  -90 ± 1 
            
Other            
Methaqualone -7 ± 2  -7 ± 2  -83 ± 2 
Sildenafil  5 ± 3  -10 ± 17  -14 ± 7 
            
Drug precursors            
Ephedrine  -2 ± 3  -57 ± 1  -81 ± 0 
Norephedrine 2 ± 3   -60 ± 1   -84 ± 0 
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Table S5 – Absolute PLE recoveries with different solvents (uppermost recovery highlighted) 
 
Compound PLE recovery (%) (n = 2, spiked amount 150 ng g
-1
)                     
 
Methanol / water (pH 2) 
               
 
1 / 3   1 / 2   1 / 1   2 / 1   3 / 1 
Stimulants 
                   
Cocaine 82 ± 0 
 
85 ± 2 
 
88 ± 2 
 
82 ± 4 
 
79 ± 3 
Benzoylecgonine 100 ± 1 
 
92 ± 1 
 
95 ± 4 
 
91 ± 9 
 
88 ± 4 
Norbenzoylecgonine 100 ± 2 
 
91 ± 1 
 
97 ± 4 
 
84 ± 9 
 
82 ± 2 
Norcocaine 95 ± 4 
 
95 ± 2 
 
91 ± 0 
 
82 ± 4 
 
81 ± 1 
Cocaethylene 86 ± 1 
 
90 ± 2 
 
92 ± 2 
 
88 ± 4 
 
87 ± 2 
Amphetamine   92 ± 11 
 
86 ± 4 
 
78 ± 2 
 
72 ± 1 
 
76 ± 3 
Methamphetamine  107 ± 3 
 
95 ± 0 
 
93 ± 1 
 
82 ± 1 
 
90 ± 3 
Methcathinone 124 ± 13 
 
122 ± 2 
 
113 ± 8 
 
81 ± 1 
 
85 ± 8 
BZP 0 ± 0 
 
1 ± 1 
 
0 ± 0 
 
0 ± 0 
 
ND ± 0 
TFMPP 66 ± 3 
 
75 ± 3 
 
81 ± 2 
 
73 ± 4 
 
77 ± 0 
                    
Hallucinogens 
                   
MDA  97 ± 5 
 
90 ± 2 
 
93 ± 3 
 
87 ± 3 
 
91 ± 5 
MDMA 104 ± 4 
 
94 ± 1 
 
94 ± 3 
 
86 ± 8 
 
92 ± 4 
MDEA 107 ± 5 
 
99 ± 1 
 
97 ± 1 
 
84 ± 4 
 
88 ± 6 
MBDB 96 ± 2 
 
94 ± 1 
 
94 ± 0 
 
89 ± 5 
 
87 ± 3 
BDB 93 ± 5 
 
89 ± 2 
 
89 ± 2 
 
82 ± 3 
 
85 ± 1 
Mescaline 93 ± 2 
 
94 ± 0 
 
92 ± 1 
 
85 ± 4 
 
96 ± 2 
LSD 67 ± 2 
 
73 ± 1 
 
87 ± 3 
 
77 ± 6 
 
66 ± 2 
O-H-LSD 110 ± 2 
 
107 ± 1 
 
93 ± 1 
 
70 ± 5 
 
63 ± 3 
                    
Opiods and morphine derivatives 
          
Heroin 109 ± 3 
 
107 ± 2 
 
109 ± 3 
 
92 ± 8 
 
85 ± 1 
6-acetylmorphine 79 ± 4 
 
78 ± 2 
 
80 ± 4 
 
72 ± 3 
 
76 ± 1 
Codeine 94 ± 4 
 
94 ± 0 
 
93 ± 3 
 
81 ± 3 
 
75 ± 0 
Norcodeine 95 ± 4 
 
95 ± 2 
 
95 ± 1 
 
84 ± 6 
 
78 ± 1 
Oxycodone 91 ± 4 
 
94 ± 1 
 
90 ± 1 
 
75 ± 3 
 
74 ± 1 
Oxymorphone 77 ± 4 
 
86 ± 2 
 
87 ± 1 
 
69 ± 1 
 
63 ± 0 
Morphine 69 ± 2 
 
71 ± 0 
 
76 ± 4 
 
76 ± 1 
 
67 ± 0 
Normorphine 70 ± 2 
 
73 ± 4 
 
77 ± 4 
 
86 ± 0 
 
79 ± 1 
Dihydrocodeine 90 ± 1 
 
89 ± 0 
 
88 ± 3 
 
75 ± 2 
 
69 ± 1 
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Buprenorphine 2 ± 0 
 
7 ± 2 
 
40 ± 3 
 
58 ± 4 
 
60 ± 2 
Norbuprenorphine 49 ± 0 
 
58 ± 2 
 
78 ± 5 
 
67 ± 4 
 
62 ± 2 
Methadone 78 ± 2 
 
86 ± 0 
 
93 ± 1 
 
83 ± 7 
 
79 ± 0 
EDDP 51 ± 3 
 
58 ± 3 
 
82 ± 4 
 
69 ± 8 
 
65 ± 2 
EMDP 92 ± 4 
 
80 ± 4 
 
89 ± 4 
 
92 ± 2 
 
91 ± 0 
Fentanyl 0 ± 0 
 
0 ± 0 
 
1 ± 0 
 
1 ± 0 
 
1 ± 0 
Norfentanyl 73 ± 0 
 
74 ± 3 
 
81 ± 0 
 
70 ± 3 
 
71 ± 0 
Propoxyphene  69 ± 11 
 
78 ± 3 
 
84 ± 3 
 
71 ± 7 
 
73 ± 1 
Norpropoxyphene 62 ± 12 
 
76 ± 1 
 
87 ± 5 
 
69 ± 8 
 
69 ± 1 
Tramadol 101 ± 4 
 
96 ± 1 
 
95 ± 1 
 
87 ± 4 
 
87 ± 5 
Nortramadol 88 ± 9 
 
76 ± 3 
 
73 ± 5 
 
61 ± 5 
 
65 ± 2 
                    
Benzodiazepines 
                   
Temazepam 31 ± 2 
 
39 ± 3 
 
84 ± 15 
 
101 ± 5 
 
68 ± 3 
Diazepam  80 ± 5 
 
101 ± 0 
 
99 ± 1 
 
93 ± 5 
 
85 ± 1 
Nordiazepam  56 ± 13 
 
75 ± 0 
 
84 ± 5 
 
82 ± 6 
 
28 ± 2 
Nitrazepam 64 ± 18 
 
77 ± 1 
 
81 ± 4 
 
66 ± 5 
 
22 ± 0 
7-aminonitrazepam 3 ± 1 
 
5 ± 3 
 
16 ± 3 
 
6 ± 2 
 
1 ± 0 
Oxazepam 67 ± 2 
 
67 ± 1 
 
104 ± 3 
 
142 ± 15 
 
139 ± 16 
Chlordiazepoxide 101 ± 1 
 
101 ± 0 
 
105 ± 2 
 
93 ± 9 
 
81 ± 3 
                    
Antidepressants  
                   
Dosulepin 65 ± 2 
 
77 ± 0 
 
87 ± 3 
 
73 ± 10 
 
68 ± 1 
Amitriptyline 65 ± 4 
 
76 ± 2 
 
88 ± 6 
 
74 ± 10 
 
67 ± 1 
Nortriptyline 82 ± 1 
 
89 ± 3 
 
100 ± 4 
 
80 ± 10 
 
69 ± 1 
Fluoxetine 23 ± 1 
 
49 ± 2 
 
84 ± 5 
 
69 ± 10 
 
67 ± 4 
Norfluoxetine 42 ± 5 
 
65 ± 1 
 
88 ± 5 
 
65 ± 10 
 
57 ± 0 
Venlafaxine 36 ± 1 
 
47 ± 4 
 
68 ± 3 
 
61 ± 7 
 
61 ± 3 
                    
Dissociative anaesthetics 
              
Phencyclidine  4 ± 0 
 
8 ± 2 
 
29 ± 2 
 
27 ± 3 
 
29 ± 0 
Ketamine  109 ± 1 
 
103 ± 0 
 
98 ± 2 
 
94 ± 0 
 
99 ± 1 
Norketamine  105 ± 5 
 
102 ± 0 
 
102 ± 2 
 
91 ± 2 
 
97 ± 3 
                    
Other 
                   
Methaqualone 88 ± 2 
 
87 ± 1 
 
91 ± 3 
 
88 ± 4 
 
77 ± 2 
Sildenafil 57 ± 4 
 
74 ± 5 
 
94 ± 9 
 
62 ± 7 
 
46 ± 2 
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Drug precursors 
                   
Ephedrine 91 ± 1 
 
88 ± 1 
 
83 ± 1 
 
68 ± 3 
 
69 ± 0 
Norephedrine 95 ± 9   89 ± 0   77 ± 1   65 ± 4   56 ± 3 
 
 
 
 
 
 
 
 
44 
 
Table S6 – Absolute PLE recoveries at different temperatures 
Compound PLE recovery (%) (n = 2, spiked amount 150 ng g
-1
) 
        
 
Extraction temperature                             
 
40°C   60°C   80°C   100°C   120°C 
Stimulants 
                   
Cocaine 57 ± 1 
 
81 ± 2 
 
86 ± 1 
 
91 ± 1 
 
95 ± 0 
Benzoylecgonine 90 ± 1 
 
96 ± 2 
 
94 ± 3 
 
96 ± 3 
 
101 ± 2 
Norbenzoylecgonine 92 ± 0 
 
94 ± 3 
 
97 ± 3 
 
93 ± 4 
 
87 ± 2 
Norcocaine 85 ± 0 
 
95 ± 1 
 
89 ± 0 
 
94 ± 3 
 
100 ± 0 
Cocaethylene 75 ± 0 
 
91 ± 0 
 
88 ± 2 
 
93 ± 1 
 
96 ± 3 
Amphetamine   98 ± 3 
 
87 ± 3 
 
82 ± 3 
 
88 ± 1 
 
89 ± 3 
Methamphetamine  90 ± 5 
 
85 ± 4 
 
84 ± 5 
 
93 ± 2 
 
95 ± 1 
Methcathinone 120 ± 1 
 
119 ± 0 
 
97 ± 5 
 
110 ± 1 
 
79 ± 9 
BZP 0 ± 0 
 
0 ± 0 
 
0 ± 0 
 
0 ± 0 
 
0 ± 0 
TFMPP 71 ± 2 
 
89 ± 0 
 
89 ± 3 
 
78 ± 5 
 
45 ± 9 
                    
Hallucinogens 
                   
MDA  85 ± 5 
 
85 ± 6 
 
93 ± 2 
 
95 ± 2 
 
92 ± 1 
MDMA 73 ± 6 
 
77 ± 8 
 
88 ± 5 
 
94 ± 2 
 
93 ± 1 
MDEA 77 ± 8 
 
83 ± 3 
 
93 ± 0 
 
98 ± 1 
 
102 ± 1 
MBDB 88 ± 1 
 
91 ± 2 
 
90 ± 0 
 
95 ± 2 
 
97 ± 0 
BDB 87 ± 3 
 
87 ± 3 
 
86 ± 1 
 
88 ± 1 
 
90 ± 2 
Mescaline 90 ± 3 
 
89 ± 1 
 
89 ± 1 
 
88 ± 2 
 
80 ± 3 
LSD 89 ± 2 
 
93 ± 0 
 
85 ± 4 
 
71 ± 4 
 
45 ± 1 
O-H-LSD 94 ± 1 
 
91 ± 2 
 
85 ± 2 
 
81 ± 3 
 
79 ± 3 
                    
Opiods and morphine derivatives 
            
Heroin 54 ± 1 
 
69 ± 1 
 
74 ± 1 
 
71 ± 3 
 
67 ± 11 
6-acetylmorphine 94 ± 2 
 
92 ± 1 
 
83 ± 0 
 
79 ± 1 
 
77 ± 2 
Codeine 89 ± 1 
 
94 ± 0 
 
88 ± 1 
 
87 ± 1 
 
82 ± 0 
Norcodeine 96 ± 0 
 
97 ± 3 
 
90 ± 2 
 
89 ± 3 
 
83 ± 1 
Oxycodone 90 ± 2 
 
93 ± 1 
 
87 ± 0 
 
84 ± 2 
 
72 ± 1 
Oxymorphone 91 ± 7 
 
92 ± 9 
 
79 ± 0 
 
76 ± 9 
 
57 ± 3 
Morphine 82 ± 4 
 
84 ± 6 
 
78 ± 1 
 
72 ± 4 
 
57 ± 2 
Normorphine 63 ± 4 
 
74 ± 6 
 
79 ± 2 
 
68 ± 2 
 
47 ± 3 
Dihydrocodeine 83 ± 1 
 
88 ± 1 
 
85 ± 0 
 
85 ± 1 
 
83 ± 1 
Buprenorphine 11 ± 0 
 
21 ± 1 
 
39 ± 3 
 
42 ± 0 
 
21 ± 7 
Norbuprenorphine 63 ± 1 
 
79 ± 2 
 
82 ± 5 
 
66 ± 7 
 
28 ± 10 
Methadone 86 ± 1 
 
96 ± 2 
 
94 ± 3 
 
90 ± 4 
 
86 ± 1 
EDDP 24 ± 4 
 
52 ± 2 
 
77 ± 4 
 
85 ± 1 
 
89 ± 0 
EMDP 71 ± 3 
 
77 ± 3 
 
87 ± 4 
 
103 ± 4 
 
96 ± 2 
Fentanyl 0 ± 0 
 
0 ± 0 
 
1 ± 0 
 
3 ± 1 
 
30 ± 1 
Norfentanyl 40 ± 1 
 
62 ± 1 
 
76 ± 0 
 
83 ± 0 
 
87 ± 0 
Propoxyphene  72 ± 2 
 
87 ± 3 
 
85 ± 3 
 
81 ± 4 
 
87 ± 4 
Norpropoxyphene 82 ± 2 
 
91 ± 1 
 
88 ± 4 
 
89 ± 2 
 
128 ± 7 
Tramadol 89 ± 1 
 
91 ± 1 
 
87 ± 2 
 
90 ± 2 
 
93 ± 2 
Nortramadol 93 ± 8 
 
94 ± 2 
 
87 ± 0 
 
93 ± 2 
 
102 ± 4 
                    
Benzodiazepines 
                   
Temazepam 60 ± 1 
 
76 ± 8 
 
92 ± 3 
 
99 ± 3 
 
77 ± 7 
Diazepam  104 ± 3 
 
103 ± 1 
 
97 ± 0 
 
92 ± 4 
 
81 ± 5 
Nordiazepam  80 ± 1 
 
84 ± 1 
 
83 ± 1 
 
74 ± 1 
 
61 ± 4 
Nitrazepam 74 ± 0 
 
82 ± 2 
 
64 ± 2 
 
57 ± 1 
 
50 ± 5 
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7-aminonitrazepam 0 ± 0 
 
1 ± 0 
 
9 ± 2 
 
19 ± 0 
 
27 ± 4 
Oxazepam 39 ± 0 
 
54 ± 10 
 
78 ± 9 
 
70 ± 13 
 
26 ± 5 
Chlordiazepoxide 83 ± 0 
 
92 ± 5 
 
84 ± 2 
 
66 ± 3 
 
31 ± 6 
                    
Antidepressants  
                   
Dosulepin 81 ± 2 
 
93 ± 5 
 
91 ± 5 
 
76 ± 6 
 
52 ± 3 
Amitriptyline 81 ± 1 
 
98 ± 1 
 
96 ± 2 
 
85 ± 9 
 
62 ± 3 
Nortriptyline 75 ± 10 
 
88 ± 2 
 
100 ± 1 
 
89 ± 8 
 
60 ± 6 
Fluoxetine 43 ± 2 
 
79 ± 0 
 
95 ± 1 
 
83 ± 9 
 
61 ± 9 
Norfluoxetine 63 ± 1 
 
89 ± 1 
 
97 ± 4 
 
79 ± 11 
 
57 ± 8 
Venlafaxine 20 ± 0 
 
42 ± 0 
 
64 ± 6 
 
74 ± 2 
 
95 ± 3 
                    
Dissociative anaesthetics 
              
Phencyclidine  3 ± 0 
 
9 ± 0 
 
27 ± 5 
 
42 ± 5 
 
74 ± 0 
Ketamine  91 ± 2 
 
90 ± 1 
 
92 ± 3 
 
100 ± 2 
 
100 ± 1 
Norketamine  94 ± 4 
 
90 ± 4 
 
93 ± 3 
 
98 ± 2 
 
92 ± 4 
                    
Other 
                   
Methaqualone 90 ± 2 
 
94 ± 0 
 
96 ± 2 
 
96 ± 4 
 
93 ± 1 
Sildenafil 54 ± 4 
 
91 ± 1 
 
93 ± 1 
 
75 ± 15 
 
54 ± 5 
                    
Drug precursors 
                   
Ephedrine 94 ± 7 
 
86 ± 1 
 
80 ± 0 
 
82 ± 3 
 
88 ± 1 
Norephedrine 103 ± 13   86 ± 2   71 ± 1   81 ± 6   85 ± 3 
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Table S7 – Standard deviation values in relation to mean values reported in Table 3 
Compound October                       November                 
 
 
WWTP A   WWTP B   WWTP C   WWTP A   WWTP B   WWTP C 
 
SPM WW %   SPM WW %   SPM WW %   SPM WW %   SPM WW %   SPM WW % 
Stimulants 
                       
Cocaine 0.1 0.8 0.0 
 
0.0 1.9 0.0 
 
0.1 2.8 0.1 
 
0.0 0.5 0.0 
 
0.1 0.2 0.1 
 
0.0 0.5 0.0 
Benzoylecgonine 0.1 4.9 0.1 
 
0.1 6.0 0.1 
 
0.0 7.7 0.3 
 
0.1 3.7 0.1 
 
0.0 5.4 0.0 
 
0.0 1.8 0.2 
Norbenzoylecgonine - 0.4 - 
 
- 0.0 - 
 
- 0.2 - 
 
- 0.1 - 
 
- 0.1 - 
 
- 0.6 - 
Norcocaine - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Cocaethylene - 0.1 - 
 
- 0.1 - 
 
0.0 0.2 0.0 
 
- 0.0 - 
 
- 0.1 - 
 
0.0 0.1 0.1 
Anhydroecgonine M.E. - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Ecgonidine  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Amphetamine   0.2 13.1 0.3 
 
2.9 2.2 0.2 
 
7.4 16.1 1.4 
 
- 1.8 - 
 
- 26.1 - 
 
0.5 39.6 0.2 
Methamphetamine  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- 0.0 - 
Methcathinone - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
BZP - 1.5 - 
 
- 0.5 - 
 
- 4.0 - 
 
9.8 2.3 0.4 
 
- - - 
 
- - - 
TFMPP 0.1 - - 
 
- 0.0 - 
 
0.2 1.7 0.2 
 
- - - 
 
- 0.0 - 
 
0.1 0.3 0.2 
                        
Hallucinogens 
                       
MDA  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
MDMA - 0.0 - 
 
- 0.3 - 
 
0.1 0.2 0.1 
 
0.0 0.3 0.3 
 
- 0.2 - 
 
0.1 1.1 0.1 
MDEA - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
MBDB - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
BDB - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Mescaline - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
LSD - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
O-H-LSD - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
                        
Opiods and morphine derivatives 
                       
Heroin - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
6-acetylmorphine - 0.1 - 
 
- 0.7 - 
 
- 0.1 - 
 
- 0.2 - 
 
- 0.2 - 
 
- 0.7 - 
Codeine 3.0 35.6 0.0 
 
4.5 33.9 0.1 
 
16.2 66.5 0.1 
 
0.4 2.7 0.0 
 
5.4 7.7 0.1 
 
16.1 32.6 0.1 
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Norcodeine 0.7 5.1 0.2 
 
- 4.8 - 
 
1.1 3.7 0.1 
 
0.2 3.3 0.1 
 
- 5.4 - 
 
- 1.7 - 
Oxycodone - 0.0 - 
 
- 0.3 - 
 
- 0.3 - 
 
- 0.6 - 
 
- 0.9 - 
 
- 0.2 - 
Oxymorphone - - 
  
- - - 
 
- 0.0 - 
 
- - - 
 
- - - 
 
- - - 
Morphine 0.7 15.2 0.0 
 
5.6 19.3 0.3 
 
0.8 9.5 0.0 
 
1.4 10.1 0.1 
 
1.0 16.6 0.1 
 
5.7 4.8 0.2 
Normorphine 0.8 23.4 0.2 
 
- 7.9 - 
 
0.1 7.3 0.0 
 
0.1 2.1 0.0 
 
- 2.0 - 
 
2.4 3.1 0.1 
Dihydrocodeine 0.6 7.0 0.1 
 
0.1 15.7 0.1 
 
0.4 5.9 0.0 
 
1.1 6.5 0.1 
 
1.1 3.5 0.1 
 
2.3 8.2 0.1 
Buprenorphine 0.0 - - 
 
- - - 
 
0.0 - - 
 
- - - 
 
- - - 
 
0.1 - - 
Norbuprenorphine - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Methadone 0.2 0.7 0.0 
 
2.1 1.8 0.1 
 
1.7 7.8 0.1 
 
0.2 2.0 0.0 
 
0.9 0.1 0.0 
 
1.3 1.9 0.0 
EDDP 1.7 1.8 0.0 
 
1.8 4.6 0.0 
 
12.3 1.7 0.1 
 
3.7 0.5 0.1 
 
3.2 1.0 0.1 
 
6.4 0.2 0.0 
EMDP 0.1 - - 
 
0.0 - - 
 
0.1 0.0 0.0 
 
0.0 - - 
 
0.0 - - 
 
0.1 0.1 0.1 
Fentanyl - - - 
 
- - - 
 
0.1 0.1 0.2 
 
- - - 
 
- - - 
 
- - - 
Norfentanyl - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Propoxyphene  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Norpropoxyphene 5.1 0.6 0.1 
 
37.0 32.6 0.8 
 
10.2 4.9 0.1 
 
1.9 48.9 0.2 
 
1.5 20.4 0.2 
 
5.7 1.3 0.1 
Tramadol 9.4 74.1 0.1 
 
4.4 20.5 0.0 
 
2.4 28.2 0.0 
 
0.1 10.7 0.0 
 
19.4 55.1 0.2 
 
56.6 85.5 0.1 
Nortramadol 11.7 60.6 0.3 
 
27.4 59.7 0.3 
 
112.4 68.8 0.6 
 
3.3 16.3 0.3 
 
34.5 66.1 0.2 
 
32.7 45.2 0.1 
                        
Benzodiazepines 
                       
Temazepam 2.5 7.0 1.2 
 
2.2 5.5 0.6 
 
- 4.3 - 
 
0.3 2.9 0.1 
 
0.8 2.1 0.4 
 
- 1.2 - 
Diazepam  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Nordiazepam  - 8.8 - 
 
- 3.9 - 
 
- 2.5 - 
 
- 1.1 - 
 
- 7.7 - 
 
- 5.9 - 
Nitrazepam - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
7-aminonitrazepam 0.7 - - 
 
- - - 
 
0.1 - - 
 
0.0 - - 
 
- - - 
 
0.1 - - 
Oxazepam - 0.1 - 
 
- 0.8 - 
 
0.5 1.6 0.1 
 
- 0.4 - 
 
- 0.4 - 
 
0.5 1.0 0.1 
Chlordiazepoxide - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
                        
Antidepressants  
                       
Dosulepin 2.1 1.4 0.0 
 
34.8 7.5 0.5 
 
22.3 3.0 0.1 
 
4.9 13.5 0.1 
 
22.3 2.7 0.3 
 
7.9 8.2 0.1 
Amitriptyline 9.5 0.4 0.0 
 
56.2 40.7 0.5 
 
14.5 3.4 0.0 
 
7.3 21.7 0.1 
 
26.1 7.8 0.2 
 
2.2 25.9 0.0 
Nortriptyline 0.5 0.0 0.0 
 
2.4 0.8 0.6 
 
4.7 1.4 0.1 
 
1.4 3.0 0.2 
 
2.6 0.3 0.4 
 
0.3 1.1 0.0 
Fluoxetine 4.8 1.8 0.1 
 
2.9 2.9 0.1 
 
10.7 2.5 0.1 
 
8.0 1.3 0.1 
 
0.7 0.8 0.0 
 
11.9 2.6 0.1 
Norfluoxetine 2.1 0.1 0.0 
 
2.6 2.0 0.2 
 
30.4 1.5 0.5 
 
2.5 0.7 0.1 
 
9.8 0.3 0.2 
 
1.8 0.7 0.0 
Venlafaxine 0.3 0.2 0.1 
 
0.1 2.5 0.0 
 
2.6 3.6 0.2 
 
0.7 4.4 0.2 
 
0.5 3.3 0.1 
 
0.5 9.8 0.1 
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Dissociative anaesthetics 
                       
Phencyclidine  - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Ketamine  0.3 1.4 0.1 
 
0.2 1.2 0.1 
 
0.2 0.4 0.1 
 
0.2 1.1 0.1 
 
0.0 0.1 0.0 
 
0.7 3.0 0.1 
Norketamine  - 0.8 - 
 
- - - 
 
- 0.7 - 
 
- - - 
 
- 0.4 - 
 
- 0.6 - 
                        
Other 
                       
Methaqualone - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
Sildenafil 0.9 0.0 0.1 
 
1.1 2.3 0.3 
 
2.5 0.3 0.2 
 
1.5 0.3 0.2 
 
2.3 0.4 0.2 
 
0.0 1.2 0.1 
                        
Drug precursors 
                       
Ephedrine - 34.2 - 
 
- 79.2 - 
 
- 203.6 - 
 
- 15.2 - 
 
- 31.1 - 
 
- 15.2 - 
Norephedrine - - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
 
- - - 
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